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Intestinal microbiota has an essential role and act like a functional organ in the body. 
Compared to other organs, the largest number of bacteria reside and produce various 
metabolites in the intestines. Gut microbiota produce short chain fatty acids (SCFAs) via 
dietary fiber fermentation. SCFAs contribute to immune homeostasis by regulating gut 
barrier function, intestinal cell proliferation, differentiation, and metabolism. Importantly, 
SCFAs control immune cell-mediated inflammation and balance immune system 
homeostasis. When the normal microbial composition is disturbed, the production of 
SCFAs is inhibited. Consequently, our body is prone to inflammation and autoimmune 
diseases.  
Moreover, the breakdown of gut microbial symbiosis results not only in inflamed 
intestines, but also in other inflamed organs, such as the lungs, skin, or kidneys tissues. 
Recently, many studies recommend the use of gut metabolites on diseases in non-intestinal 
tissues.  Accordingly, understanding SCFAs effect on the immune system will provide 
therapeutic application for various immune disorders. Our studies investigated the roles of 





In Part I, we examined the role of SCFAs in T cell differentiation and T cell-
dependent intestinal inflammation and immunity. Major SCFAs-acetate, propionate, and 
butyrate-enhanced Th1/Th17 effector T cell differentiation. SCFAs also promoted IL-10+ 
T cell generation in effector T cell-inducing conditions. SCFA-treated T cells showed 
suppressive and anti-inflammatory activity via IL-10 expression in colitis models. 
Moreover, SCFAs enhanced Th17 cell during bacterial infection and efficiently cleared 
invading pathogens. GPR41 and GPR43 are major SCFA receptors, but expression in T 
cells was not detected. SCFAs promoted T cell differentiation in a GPR41 and GPR43 
independent manner. Instead, we suggested that SCFAs utilize other mechanisms and 
regulate T cell differentiation. First, SCFAs stimulated mTOR activity in T cell 
differentiation. Next, we found that SCFAs inhibited histone deacetylase (HDAC) activity 
and upregulated acetylation of p70 S6 kinase, a kinase of mTOR, in T cells.  
In Part II, we investigated the role of SCFAs in the renal system. We exposed mice 
to a high concentration of SCFAs in drinking water for up to six weeks. The treatment 
caused a profound effect on ureteral obstruction, which developed into hydronephrosis. T 
cell or gut microbiota is required in SCFAs-mediated renal inflammation. In affected 
tissues, Th1 or Th17 cells were increased and the neutralization of IL-17 or IFNγ inhibited 
disease progression. We found that SCFAs activated mTOR signaling in renal T cells and 
developed T cell-dependent inflammation. Moreover, rapamycin administration protected 
the host from SCFA-induced renal disease.    
We studied the roles of SCFAs in T cell differentiation and T cell-dependent 
inflammatory diseases. We speculate that SCFAs have binary roles in immune regulation. 





inflammation or fight against invading pathogens. In the renal system, SCFAs developed 
unexpected ureteral obstruction and kidney inflammation. This suggests that excessive 
SCFAs can result in unexpected inflammatory diseases of peripheral organs. Although 
SCFAs are produced in the colon, they regulate inflammation in remote organs; therefore, 








CHAPTER 1. LITERATURE REVIEW 
1.1 Regulation of short chain fatty acids on T cell differentiation and intestinal 
inflammation. 
 
1.1.1 Short chain fatty acids production in the intestines by commensal 
bacteria 
 
In the gastrointestinal tract, microbial metabolites play a critical role in the 
maintenance of intestinal homeostasis. Microbial products are used by the host as nutrients 
and are regulating factors for the host immune system (1). Short chain fatty acids (SCFAs) 
are a major group of gut metabolites produced by colonic microbiota from fermenting non-
digestible fiber. Acetate (C2), propionate (C3), and butyrate (C4) are the most abundant 
SCFAs and have 2~4 carbons (2). In the large intestine, the molar ratio of is these SCFAs 
are 50:20:20 respectively, and the total concentration is ~130mM (3-5).  
While starch or starch-like polysaccharides are absorbed in the upper gastrointestinal 
(GI) tract, nonstarch polysaccharides (NPS) remain undigested. Accordingly, 
anaerobicbacteria in the proximal colon produce each SCFA by different mechanisms. 
Acetogens, such as Firmicutes produce C2 via Wood–Ljungdahl pathway, which converts 





bacteria produce C3 through three mechanisms: succinate, arylate or propanediol 
pathways (9). C4 is produced by bacteria that expresses the genes that encode butyryl CoA 
/ acetyl CoA transferases (10).   
Bacterial composition impacts SCFA production. There are ~1,000 different species 
of gut microbiota. The gut microbiota composition is altered by environmental factors like 
diet, which changes the production of SCFAs. For example, when mice are fed a high-fiber 
diet, Bacteroidetes or Actinobacteria are abundant in cecal contents, while Firmicutes and 
Proteobacteria populations are scarce (11). Taking this into consideration, sustaining the 
normal population of beneficial microbiota is required for beneficial metabolite production. 
SCFAs regulate energy metabolism, cell differentiation, proliferation, and gene 
expression in the host. Several different pathways mediate SCFA function. SCFAs are 
absorbed into colonocytes through anionic diffusion (Na+ or K+ & H+ exchange) or 
monocarboxylate transporters (MCTs) such as H+-coulpled MCT1 (12-14). Furthermore, 
SCFAs activate a number G protein coupled receptors (GPCRs) (15). Among various 
GPCRs, SCFAs activate GPR43 and GPR41, which are highly expressed in human adipose 
and intestinal tissues (16). While, shorter SCFAs, such as acetate and propionate, have a 
higher GPR43 affinity, propionate and butyrate show preferred binding to GPR41(17).  
GPR109A is a niacin (vitamin B3 or nicotinate) receptor and is highly expressed in 









1.1.2 T cell development and differentiation 
 
T cells are mainly produced in the thymus. Initially, T cell expresses neither CD4 
nor CD8. When lymphoid progenitors are introduced to the thymus, CD4 and CD8 double 
negative thymocytes develop into αβ-TCR expressing cells, which are double positive for 
CD4 and CD8. Subsequently, they become mature single-positive cells (CD4+ or CD8+) 
(20, 21). CD4+ T cells are maintained in a naïve form in secondary lymphoid tissues, such 
as the spleen or lymph nodes. Upon antigenic signaling or cytokines stimulation, naïve T 
cells differentiate into Th1/Th17 effector T cells and regulatory T cells in peripheral organs 
(22). The IL-12 family signals differentiation in Th1 cells, which express inflammatory 
cytokines, such as IFNγ, and fight against intracellular pathogens.  In the last decade, Th17 
cells caught the attention of immunologists due to its inflammatory impact in autoimmune 
diseases. IL-6, IL-23, and TGFβ1 signals stimulate naïve CD4+ T cells to differentiate into 
Th17 cells, which produce IL-17. During Th17 cell differentiation, RoRγt, a major 
transcription factor, is activated (23, 24). Regulatory T cells, such as IL-10 producing T 
cells are generated by IL-27 signals and have anti-inflammatory functions. The 
combination of TGFβ1 and IL-2 induces fox-head box P3 (FoxP3) expressing cells, which 
is characterized by immune suppressive functions(25, 26).Moreover, chemokines or gut 
metabolites are involved in T cell differentiation. For example, CCL2 suppresses IL-12 
mediated Th1 differentiation, but supports Th2 generation (27). Retinoic acid (RA), a small 
intestine metabolite, supports FoxP3+ T cell generation, but blocks IL-6 induced Th17 cell 






1.1.3 Role of SCFAs in T cell differentiation and underlying mechanisms 
Recent studies reported the role of SCFAs in T cell differentiation and investigated 
the related molecular or intracellular mechanisms. Furusawa et al. showed that C4 
treatment elevated FoxP3+ T cell expression both in vitro and in vivo. In colonic lamina 
propria, FoxP3+ cells were expanded by C4 feeding. C4 also increased the generation of 
FoxP3+ T cells not only in Tregs but also in Th1/Th17 polarizing culture conditions; the 
level of transcription factors, T-bet or RoRγt were unchanged. As an intracellular 
mechanism, the authors suggested that C4 enhanced H3 acetylation in the Foxp3 promoter 
region or the conserved non-coding sequence (CNS) regions. However, C4 did not affect 
the acetylation of other transcription factors, tbx21, Gata3,or Rorc (29). A complementary 
study examined the effect of C3 and C4 in regulatory T cell induction. C4 feeding increased 
the population of colonic FoxP3+ T cells in a CNS1 dependent manner. However, 
antibiotics feeding decreased fecal C3 and C4 concentrations, and subsequently suppressed 
FoxP3+ T cell expansion in the colon. This suppression was reversed by oral SCFA 
administration (30).  
A number of studies disputed the role of SCFA receptors in T cell differentiation. 
A study reported that GPR43, a major SCFA receptor, played an essential role in regulatory 
T cell generation. C2, C3, and C4 treatment augmented populations of colonic FoxP3+ and 
IL-10+ T cells. C3, especially, enhanced HDAC6 inhibition and H3 acetylation in a GPR43 
dependent manner (31). Another article suggested the role of GPR109a, a receptor for both 
niacin and C4, in regulatory T cell expansion. GPR109a-deficient mice showed decreased 
colonic FoxP3+ and IL-10+ T cell populations; this strain was more susceptible to DSS-





receptors, our group showed that GPR41 and GPR43 are not necessary in SCFA-promoted 
T cell differentiation. The expressions of GPR41 and GPR43 in splenic or colonic CD4+ T 
cells were are low. Accordingly, SCFA-enhanced IL-10+ T cell and Th1/Th17 cell 
differentiation occurred independently of GPR41 and GPR43. Instead, we suggest that C2, 
C3, and C4 regulate HDAC and mTOR activity for both effector and regulatory T cell 
differentiation. A recent study showed similar data, that C4 increased Th1/Th17 cell 
differentiation and FoxP3+ T cell induction (32). These studies agreed on the common 
effects of SCFAs on regulatory T cell generation, while effector T cell induction is 
regulated in defined conditions. Yet, the effect of SCFA receptors in T cell regulation must 
be investigated further. 
1.1.4 Beneficial effect of SCFAs on intestinal inflammation 
So far, we have discussed the production of SCFAs and the mechanisms of SCFA 
enhanced T cell differentiation. Next, we will discuss the effect of SCFAs on intestinal 
inflammation. Gut microbiota produces SCFAs, which are absorbed into intestinal tissue 
through epithelial cells. Absorbed SCFAs provide energy to colonocytes and contribute to 
general colonic health (33). In human studies, SCFAs administration ameliorates colitis. 
For example, dietary changes expanded SCFA-producing bacteria, which suppressed 
intestinal inflammation(33, 34).  
SCFAs regulate immune system by indirect or direct mechanisms and control 
intestinal inflammation. First, SCFAs activate major G-protein-coupled receptors (GPCR), 
such as GPR41, GPR43, and GPR109a. These receptors are highly expressed in gut 
epithelial cells and in neutrophils. When SCFAs activate GPCRs, intestinal integrity is 





the role of GPR43 in intestinal inflammation was demonstrated by several studies. In 
GPR43-deficient mice, SCFA signals vanished, which exacerbated DSS-induce colitis as 
compared to WT mice. Oral SCFA administration ameliorated neutrophil infiltration and 
inflammation dependent on GPR43. This study further confirmed the role of GPR43 in 
hematopoietic cells using bone marrow chimeras. When WT mice were reconstituted with 
GPR43-deficient bone marrow cells, these mice showed severe colitis as GPR43 deficient 
mice(36). However, a contrasting role of GPR43 was also suggested. In GPR43-deficienct 
mice, a chronic DSS-induced inflammation was less severe and intestinal neutrophils were 
less infiltrated than in WT mice. When GPR43-deficient mice were exposed to chronic 
inflammation, MAPK-dependent neutrophil migration was defective, which resulted in 
milder inflammation. However, GPR43-deficient mice were more susceptible to acute DSS 
colitis than WT mice, due to the disruption of gut integrity (37). Our group also reported 
the role of GPR41 and GPR43 in ethanol- or TNBS-induced colitis. In GRP41- or GPR43-
deficient conditions, leukocyte recruitment was impaired and mice developed milder 
inflammation. However, due to the defective function of SCFA-receptors, GPR41- or 
GPR43-deficient mice were unable to clear infected bacteria and intestinal permeability 
was damaged (38).  
SCFAs directly regulate intestinal inflammation through epigenetic modification. 
SCFA-mediated histone acetylation regulates immune cell differentiation and controls 
intestinal inflammation. In experimental colitis models, HDAC inhibitors showed 
protective effects against DSS- or TNBS-induced colitis. HDAC inhibitor treatment with 
SAHA or ITF2357 ameliorated intestinal inflammation by suppressing inflammatory 





inflammation. Deletion of intestinal epithelial HDAC1 and HDAC2 changed the function 
and structure of epithelial cells. In neutrophils, SCFAs suppressed TNFα expression and 
inhibited the Nf-κB pathway, which is linked to HDAC inhibition. In macrophages, the 
anti-inflammatory effect of SCFAs was suggested as well. C4 treatment suppressed 
inflammatory cytokine expression in colonic macrophages both in vivo and in vitro. 
Authors provided a mechanism for C4 enhanced histone 3 lysine 9 (H3K9) acetylation of 
Nos2, Il6, and Il12b promoter regions in bone marrow derived macrophages (BMDM) (41-
43). 
The T cell is a major cell type involved in intestinal inflammation. Previously, we 
discussed that SCFAs control T cell differentiation through HDAC activation in GPR41- 
and GPR43- independent manners. Then, we examined the effect of SCFAs in T cell-
mediated colitis. In a T cell adoptive transfer model, SCFA-treated T cell showed less 
inflammatory action. Oral SCFA administration decreased the inflammatory response to  
anti-CD3 in a IL-10 dependent fashion (44). A different study reported that colonic FoxP3+ 
T cells, which have anti-inflammatory functions, were enhanced by SCFAs treatment 
independent of GPR109a. Furthermore, SCFA induced histone H3 acetylation in FoxP3 
promoter and the FoxP3 enhancer-conserved non-coding sequence 1 (CNS1) was required 
in SCFA-mediated FoxP3+ T cell generation (30).  A similar study showed the beneficial 
role of SCFAs in T cell-mediated colitis. The adoptive transfer of naïve CD4+ T cell into a 
C4-diet fed RAG1-deficient host resulted in less inflammation than mice with standard diet. 
FoxP3+ T cells expanded in the colonic lamina propria of C4-diet fed mice; however C2 or 
C3 feeding was unable to ameliorate T cell-mediated inflammation (29). We demonstrated 





enhanced T cell differentiation independent of GPR43. However, a study suggested that 
SCFAs ameliorate T cell-mediated colitis in a GPR43-dependent manner. T cells of WT 
mice suppressed naïve T cell induced colitis in SCFA-fed RAG1-deficient hosts, while 
cells from GPR43-deficient mice did not suppress intestinal inflammation (31).  
 
1.2 Immune cell regulation of renal disease development and its underlying mechanisms. 
 
1.2.1 The role of T cell and cytokines in renal inflammation. 
 
The T cell is a major regulator of renal inflammation, and a number of renal disease 
models demonstrate the critical role of the T cell. In the unilateral ureteral obstruction 
(UUO) model, the essential role of the CD4+ T cell was reported. CD4+ T cell depletion or 
RAG1-deficiency, protected mice from UUO-induced inflammation and fibrosis. There 
was reduced collagen accumulation in the interstitial area of SCFA-treated mice (45). 
Similarly, our study showed that αβ-T cell deficiency inhibited gut metabolites-induced 
ureteral obstruction and inflammation (46). Antigen stimulation activates effector T cell 
generation, which promotes inflammatory cytokine secretion. T cell-mediated 
inflammatory cytokines, such as IL-17 and IFNγ are responsible for renal inflammation. 
The role of renal T cells was demonstrated in the anti-glomerular basement membrane 
(GBM) glomerulonephritis as well. Effector CD4+ or CD8+ T cells, which produce IL-17 
or IFNγ, accumulated in the tubulointerstitial region of the inflamed kidneys (47). The 
concise action of effector T cells was confirmed in an antigen specific glomerulonephritis 





inflammation in OVA-bearing RAG-deficient mice (48). The role of IL-17 was also 
identified in fatal lupus glomerulonephritis. In lupus-prone mice, IL-17 deficiency 
protected fatal glomerulonephritis (49). T cells are stimulated by other immune cells, such 
as antigen-presenting cells (APCs) that provide inflammatory cytokines. For instance, 
dendritic cell (DC) produced IL-1, which induces of IL-17A production by renal T cells 
(46, 50). In obstructed kidneys, T cells and DCs were collated and induced Th1 or Th17 
cells (51). In addition, renal resident cells, tubular epithelial cells interacted with T cells 
and affected effector T cell generation in kidney tissues (52). These findings support the 
role of the T cell and the mutual interaction between T cell and APCs in renal inflammation 
pathogenesis.  
 
1.2.2 mTOR signaling and the effect of mTOR inhibition in renal disease 
 
mTOR signaling has a critical function in immune cell proliferation and 
differentiation. mTORC1, a downstream signal of mTOR, is required for effector CD4+and 
CD8+ T cell differentiations (53, 54). mTOR activation also regulates IL-10+ T cell 
generation (44). Besides, mTOR signals control non-T cell regulation, such as B cell or 
DC maturation (55, 56). Because antibody or cytokine production from these non-T cells 
affects T cell differentiation (57),better understanding of mTOR regulation in immune cells 
is required to control inflammatory disorders.  
In this regards, the mTOR pathway is involved in the development of a number of 
renal diseases. Our group reported that increased mTOR activity in renal CD4+ T cells 






S6K pathway, a key downstream of mTOR, was activated (58). mTORC2 is a mTOR 
kinase component and its deletion abrogated TGFβ1-dependent kidney fibrosis (59). 
Because mTOR activation leads to renal inflammation, an mTOR inhibitor, rapamycin, 
was utilized in various kidney disease models. In an UUO model, the rapamycin 
application protected host mice from diseases, by reducing the infiltration of collagen fiber, 
macrophages, and effector T cells in kidney tissues (46, 60, 61). Rapamycin also inhibited 
mTOR activity in PKD mice, which blocked renal cyst formation and recovered renal 
function. In Han:SPRD rats, a PKD-prone strain, rapamycin prohibited PKD pathogenesis, 
via reducing kidney cyst volume density and blood urea nitrogen (BUN) levels. Rapamycin 
treatment protected rodents from anti-GBM antibody-induced glomerulonephritis by 
suppressing inflammatory immune cell infiltration and proteinuria (62, 63).Because mTOR 
activation is responsible for renal inflammation development, many renal disorders can be 
prevented or relieved with mTOR pathway inhibition.   
Although the beneficial impact of rapamycin on renal disease is clear, how mTOR 
signaling controls intracellular processes is still a question of interest. mTOR pathways 
regulate endoplasmic reticulum (ER) stress and ER stress is associated with renal diseases. 
A recent study suggests that mTOR signaling increases ER stress, which promotes tubular 
cell apoptosis(64, 65). In the rat minimal-change disease (MCD) model, mTORC1 
activation enhanced ER stress, which resulted in glomerular podocyte damage and 
proteinuria(66). Accordingly, it is worth studying whether or not mTOR activation 








1.2.3 Involvement of HDAC in renal disease 
 
In the previous section, we discussed that SCFA-mediated HDAC inhibition has 
beneficial effects on intestinal inflammation. A number of HDAC inhibitors are also 
applied to control renal inflammation in both human patients and animal research. 
Trichostatin A (TSA) is a pan-HDAC inhibitor, which has inhibitory effects on HDAC 
class I and II. TSA treatments were applied to renal disease models, which attenuated 
fibronectin expression in UUO mice. In addition, suppressed STAT3 activity and cellular 
apoptosis were observed in TSA-treated mice (67). A later study investigated the effect of 
HDAC class I-specific inhibitor in obstructed kidneys. An intraperitoneal injection of 
HDAC I inhibitor controlled fibrosis and TGFβ1 expression. Moreover, epidermal growth 
factor receptor (EGFR) activity was suppressed by HDAC I inhibitor followed by Smad-3 
abrogation (68). The beneficial effects of HDAC inhibitors on renal diseases were 
confirmed in an acute kidney injury model as well. Pre-treatment application of valproic 
acid or acetate supported regular renal function and protected against ischemia-reperfusion 
injury (69, 70).  
In addition, the therapeutic potential of HDAC inhibitors is suggested as follows. 
When methyl-4-(phenylthio) butanoate was administrated one day after ischemia-
reperfusion injury, tubular epithelial apoptosis and fibrosis were attenuated (71). Although 
it is uncertain whether or not HDAC inhibitors protect disease through histone acetylation 
or other pathways, HDAC inhibitors are a promising tool for the maintenance of various 







1.2.4 The role of gut microbiota and metabolite in renal disease 
 
The human body accommodates more than 100 trillion microbiota, collectively 
considered an internal organ due to its essential role. When the homeostatic composition 
of microbiota is disrupted, the human body is vulnerable to diseases including renal failure. 
Healthy people had more diverse bacterial populations than end-stage renal disease (ESRD) 
patients, who had decreased compositions of Firmicutes, Actinobacteria, and 
Proteobacteria. Rats with Chronic kidney disease (CKD) had less Lactobacillaceae and 
Prevotellaceae than the healthy control population (72). As pathobionts expanded, 
intestinal toxic metabolites disorganize gut junction and barrier function. In CKD rats, the 
level of gut junction proteins, such as ZO-1, occludin, and claudin-1 were reduced (73). As 
a result, gut permeability was increased and hosts were more vulnerable to kidney diseases. 
In addition, urase-processing bacteria was increased in ESRD patients and induced urea 
accumulation in the intestinal tract (74).  
It is possible that a growing pathogenic bacteria population relates to diet. Food 
restriction protected PKD-prone mice from cellular injury, cyst formation, and helped 
normal kidney function (58). To treat microbial-induced renal diseases, many studies 
applied antibiotics. Our recent study also showed that oral vancomycin feeding prevented 
ureteral obstruction (46, 75, 76). However, the risk of antibiotic treatment on renal diseases 
was also demonstrated. Broad-spectrum antibiotics treatment elongated renal failure in 
human patients. Moreover, oral administration of fluoroquinolone increased the risk of 






To overcome the adverse effect of antibiotics, benign gut metabolites were applied 
to treat renal diseases. A couple of studies demonstrated the beneficial effect of SCFAs on 
acute kidney injury (AKI). SCFA treatment inhibited NFκb activation and inflammatory 
cytokine accumulation. Delivering SCFA-producing bacteria, such as Bifidobacterium 
restored renal function after AKI as well (76, 80). Butyrate treatment attenuated TGF-β1 
and Smad3 activation in renal epithelial cell cultures, which suppressed renal fibrosis (81). 
RA, a metabolite of the small intestine, inhibited fibrosis in UUO mice by ameliorating 
TGF-β1 expression and collagen deposition (82). While SCFAs have beneficial effects, 











CHAPTER 2. IMPACT OF GUT METABOLITES SHORT CHAIN FATTY ACIDS 
ON EFFECTOR AND REGULATORY T CELL DIFFERENTIATION 
2.1 Introduction 
 
 From an immunological perspective, a healthy life means maintaining the balance 
of the immune system. T cells are a major player in the immune system because they 
control inflammation and host immunity. T cells are produced in the thymus and stored in 
lymphoid tissue in a naïve form. When naïve T cells are stimulated by several signals, such 
as cytokines and co-stimulatory molecules, they differentiate into effector T cells or 
regulatory T cells. Effector T cells secrete inflammatory cytokines, fight against invading 
pathogens, and induce inflammation. On the other hand, regulatory T cells have anti-
inflammatory or immune suppressive functions.  
Food significantly affects healthy life because gut microbial metabolites regulate 
the immune system and control the homeostasis of body. Short chain fatty acids (SCFAs) 
such as acetate (C2), propionate (C3), or butyrate (C4) are major microbial metabolites 
produced by the fermentation of dietary fiber. SCFAs have various functions and contribute 
to healthy physiological condition by regulating gut mobility and providing an energy 
source to intestinal cells.  
In this study, we investigated the role of SCFAs in T cell regulation and intestinal 






SCFAs enhanced effector T cell differentiation. SCFA-treated T cells showed 
suppressive function in T cell-dependent inflammation and promoted anti-bacterial 
immunity. In addition, our study suggests the mechanisms by which SCFAs shape T cell 
differentiation. We propose that SCFAs inhibit histone deacetylases and increase mTOR 
activity in T cells, which is required for generation of both effector and regulatory T cells. 
 
2.2 Materials and methods 
 
Mice 
C57BL/6 mice were from Harlan. CD45.1 C57BL/6 mice, Rag1(-/-) (B6.129s7-
Rag1 tm1Mom/J) mice, and IL-10(-/-) mice were from the Jackson laboratory. GPR43(-/-) 
mice were from Deltagen (San Mateo, CA), and GPR41(-/-)  mice were obtained from Dr. 
M. Yanagisawa (UT Southwestern Medical Center at Dallas). All mice were kept at Purdue 
University for at least 12 months before use. All experiments with animals in this study 
were approved by the Purdue Animal Care and Use Committee (PACUC).  
 
T cell isolation 
For Naïve CD4+ T cell isolation, total CD4+ T cells were isolated from the spleen 
and lymph nodes, using the CD4+ T cell isolation kit (Miltenyi). For further depletion, PE-
conjugated antibodies to CD8 (clone 53-6.7), CD19 (clone 6D5), CD25 (clone 3C7), CD44 
(clone IM7), and CD69 (clone H1.2F3) and anti-PE microbeads were applied. CD8+ cells 
were isolated by the CD8+ T cell isolation kit (Miltenyi), and cells expressing CD4, CD19, 






GPR41 and GPR43 expression in various cell types 
For qRT-PCR and conventional PCR analysis of GPR41 and GPR43 in different 
cell types, colonic epithelial cells were positively selected by biotin conjugated anti-CD326 
(clone Ep-CAM) and anti-biotin microbeads. To collect colonic T cells, non-T cells were 
deleted by biotin conjugated anti-CD11c (clone N418), CD19 (clone 6D5), CD326 (clone 
Ep-CAM), and Gr-1 (clone RB6-8C5) antibodies and anti-biotin microbeads. Total CD4+ 
cells were isolated using PE-conjugated anti-CD4 antibody and anti-PE microbeads. 
Marrow Gr-1+ cells were positively isolated from total bone marrow cells by biotin-labeled 
anti-GR-1antibody (clone RB6-8C5) and anti-biotin microbeads. The purity of the isolated 
each cell types was higher than 95%. Conventional PCR was performed with 28 cycles for 
β-actin and 35 cycles for GPR41 and GPR43 at 55°C annealing temperature. 
 
T cell differentiation in vitro 
Naïve CD4+ or CD8+ T cells from wild type, GPR41(-/-), and GPR43(-/-) mice 
were activated with plate-bound anti-CD3 (1-5 g/ml) and soluble anti-CD28 (2 g/ml) 
for 3-6 days in the presence or absence of Sodium Acetate (C2), Sodium Propionate (C3), 
or Sodium Butyrate (C4) at indicated concentrations (0.1-10 mM). Effector or regulatory 
T cells were induced in following polarizing conditions in normal RPMI 1640 medium (10% 
FBS). For the non-polarized condition (Tnp), hIL-2 (100 U/ml) was used. For Th17/Tc17 
cells, hTGF-β1 (5 ng/ml), mIL-6 (20 ng/ml), mIL-1β (10 ng/ml), mIL-23 (10 ng/ml), mIL-
21(10 ng/ml), mTNF-α (20 ng/ml), anti-mIL-4 (11B11, 10 µg/ml), and anti-mIFN-γ 
(XMG1.2, 10 µg/ml) were used. For Th1/Tc1 cells, hIL-2 (100 U/ml), mIL-12 (10 ng/ml), 






ng/ml) were used. Rapamycin (25 nM), metformin (1,1-dimethylbiguanide hydrochloride, 
1 mM), or TSA (trichostatin A, 10 nM) was used for the T-cell culture.  
 
Flow cytometry 
For intracellular staining of IL-10, IL-17 and IFN, cells were stained first for 
surface antigens with antibodies (e.g. RM4-5 for CD4 or 53-6.7 for CD8) and then 
activated in RPMI 1640 (10% FBS) with PMA (50 ng/ml), ionomycin (1 μM), and 
monensin (2 mM; Sigma-Aldrich) for 4 hours. Cells were then fixed, permeabilized, and 
stained with antibodies to mIL-10 (JES5-16E3), mIL-17A (TC11-18H10.1), or IFN-γ 
(XMG1.2). Cells were stained with an antibody to mouse FoxP3 (FJK-16s), T-bet 
(eBio4B10), or RORγt (AFKJS-9) according to the manufacturer's protocol. For co-
staining of IL-10 and FoxP3, cells pre-stained with anti-CD4 (RM4-5) were activated 
with PMA (50 ng/ml), ionomycin (1 μM), and Brefeldin A (25 g/ml) for 4 hours. 
Activated cells were fixed, permeabilized and stained with antibodies to IL-10 (JES5-
16E3) and FoxP3 (FJK-16s). 
For the assessment of mTOR activation and STAT3 activation, isolated mouse 
CD4+ cells were prepared. Cells were activated for up to 60 hours in complete RPMI-1640 
medium with an immobilized antibody to CD3 (5 µg/ml) and soluble antibody to CD28 (2 
µg/ml) in the presence of C2 (0-20 mM), C3 (0-1 mM) or C4 (0-0.5 mM). Antibodies to 
phosphorylated rS6 (Ser235/236; D57.2.2E), phosphorylated STAT3 (Y705; D3A7), and 









The microarray study was performed using Mouse 430 2.0 chips (Affymetrix, Santa 
Clara, CA) as described previously (83). Raw intensity signals were obtained with 
GeneChip Operating Software (Affymetrix) and normalized with the signals of a 
housekeeping gene (β-actin). The heatmap plot of up- or down-regulated genes was drawn 
using Treeview (http://rana.lbl.gov/EisenSoftware.htm). The microarray data have been 
deposited to the Gene Expression Omnibus site (accession number: GSE31585). 
 
Quantitative real-time PCR analysis and ELISA 
Total RNA was extracted with TRIzol® (Invitrogen), and cDNA synthesis was 
performed with SuperScript® II Reverse Transcriptase (Invitrogen). Quantitative real-time 
PCR (qRT-PCR) was performed with Maxima® SYBR Green/ROX qPCR Master Mix 
(2X) (Fermentas).  
The primers used were:  
IL-10 (CCA.GCT.GGA.CAA.CAT.ACT.GCT and 
CAT.CAT.GTA.TGC.TTC.TAT.GCA.G);  
IL-17A (GAC.TCT.CCA.CCG.CAA.TG and CGG.GTC.TCT.GTT.TAG.GCT);  
IL-17F (CCA.TGG.GAT.TAC.AAC.ATC.ACT.C and 
TTG.TAT.GCA.GCG.TTG.TCA.G);  
RoRγt (AGC.CAC.TGC.ATT.CCC.AGT.TTC.T and 
TGA.AAG.CCG.CTT.GGC.AAA.CT);  






IFN-γ (AGA.CAA.TCA.GGC.CAT.CAG.CA and 
CGA.ATC.AGC.AGC.GAC.TCC.TTT);  
T-bet (ATG.CCG.CTG.AAT.TGG.AAG.GT and 
ACC.TCG.CAG.AAA.GCC.ATG.AAG.T).  
Gene expression levels were normalized by -actin levels. ELISA of secreted IL-10 was 
performed with anti-mIL-10 antibody (JES5-2A5) and a biotinylated anti-mIL-10 antibody 
(JES5-16ES). 
 
Assessment of in vitro suppressive activity 
Naïve CD4+ T cells were cultured for 5-6 days in a Th1 condition in the presence 
(C2-treated cells) or absence (control cells) of C2. Suppression activity on freshly isolated 
CD4+ CD25- T cells was examined. Responder cells, CD4+ CD25- T cells (5 × 104/well) 
were isolated from the spleen of CD45.1 congenic mice, and cultured T cells (suppressors) 
were co-cultured in U-bottomed 96-well plates for 3 days at the indicated ratios in the 
presence of anti-CD3 (2.5 µg/ml) and 104 irradiated T cell-depleted splenocytes as antigen 
presenting cells (APCs). Dilution of carboxy fluorescein diacetate succinimidyl ester 
(CFSE) was assessed by flow cytometry. 
 
T cell mediated colitis in Rag1(-/-) mice 
The control and C2-treated T cells (prepared in a Th17 or Th1 condition) were 
separately injected i.p. into Rag1-deficient (B6.129s7-Rag1 tm1Mom/J) mice (1 million 
cells/mouse). The mice were monitored daily for weight change and activity. All mice were 






other tissues were examined for the frequencies of Th1, Th17, and FoxP3+ T cells by flow 
cytometry. Intestinal tissues were embedded in paraffin, cut into 6 μm-thick sections, and 
stained with hematoxylin and eosin. Tissue inflammatory scores were assessed based on 
the degree of leukocyte infiltration and mucosal hyperplasia on a scale of 0–4. The 
histological images were obtained with a wide field Leica microscope equipped with a 
color camera at 100× magnification (scale bar: 200 m). 
 
C2 feeding effect on effector and regulatory T cell subsets in vivo. 
WT C57BL/6, GPR43(-/-), and GPR41(-/-) mice were kept on drinking water 
containing C2 (200 mM, pH 7.5) from 3 weeks of age for 6-8 weeks. Drinking water was 
replaced once a week. Frequencies of indicated T cell subsets in various organs were 
determined by flow cytometry. To boost T cell activity, C2-fed WT or IL10-deficient mice 
were injected with anti-CD3 (15 g/mouse, clone 145-2C11) at twice (0 and 48 h) and 
were sacrificed at 52 h after the first injection of anti-CD3. Alternatively, mice were 
infected with C. rodentium (DBS100, 1010 CFU/mouse) via oral gavage as described 
previously (38). After 2 weeks, infected mice were sacrificed, and indicated tissues were 
examined for frequencies of T cell subsets with flow cytometry. Intestinal inflammation 
was accessed based on the degree of leukocyte infiltration, mucosal hyperplasia, and loss 
of villi on a scale of 0–5. 
 
Cell-based HDAC inhibitor assay and assessment of S6K acetylation in T cells 
SCFA-induced HDAC activity in T cell was assessed with an HDAC Cell-Based 






GPRs-KO mice and were pre-activated with plate-coated anti-CD3 (5 g/ml) and soluble 
anti-CD28 (2 g/ml) for 2 days. The activated T cells were incubated with C2, C3, or 
TSA for 2 hours and the cellular HDAC activity was determined according to the 
manufacturer’s protocol.  
CD4+ T cells were activated with anti-CD3/CD28 and hIL-2 (100 U/ml) in the 
presence or absence of C2 (10 mM), C3 (1 mM), or TSA (10 nM) for 3 days. Cultured cells 
(1 × 107 cells) were lysed, pre-cleared by Protein A agarose beads, and incubated with 
acetylated-lysine antibody (# 9441, Cell Signaling Technology) overnight at 4ºC. Antigen-
antibody complexes were precipitated with Protein A agarose beads. Immunoprecipitates 
or total cell lysate (40 µg of protein/well) were separated with SDS-polyacrylamide gels 
and then transferred onto nitrocellulose membranes (Bio-Rad). After blocking 1 h in a 
nonfat dried milk, membranes were incubated with mAb to p70 S6 Kinase (49D7, 
biotinylated, Cell Signaling Technology) overnight at 4ºC. The membranes were 
developed with HRP Streptavidin (Biolegend) and the ECL detection system (GE 
Healthcare) using a G:BOX (Syngene). 
 
Measurement of SCFAs concentrations in C2-fed mice 
Intestine tissues and cecal content (100 mg) were collected from normal or C2-
water fed mice and homogenized in 900 µl of water and 1.4 mm ceramic beads using a 
Precellys®24 homogenizer. The homogenates were labeled with regular aniline (12C6), and 
external SCFA standard solution (10 mg/ml of C2, C3, and C4) was labeled with aniline-
13C6 using N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, 2 






mixture was incubated for 2 h, and triethylamine (TEA) was added to stop the labeling 
reaction. The samples and standard reaction solution were mixed (1:1) and analyzed with 
an Agilent 6460 Triple Quad LC/MS System (Agilent Technologies). SCFAs were 
separated with a CN column (4.6×150 mm) at gas temperature of 325oC, gas flow rate of 
8 L/min,  nebulizer pressure of 45 psi, sheath gas temperature of 250oC, sheath gas flow 
rate of 7 L/min, capillary voltage of +3500V, and nozzle voltage of +1000V.  SCFA 
concentrations in samples were determined based on peak areas of the internal and external 
standards.   
 
Statistical analysis 
Student’s paired t test (2-tailed) was used to determine the significance of the 
differences between two the groups. Mouse weight change data was analyzed with a 
repeated measures analyses of variance (ANOVA, SAS, version 9.2, SAS Institute Inc. 




Major SCFAs acetate (C2) and propionate (C3) promote naïve T cell differentiation 
into Th1 or Th17 effector T cells 
Toexplore the role of SCFAs in effector T cell differentiation, we cultured naïve 
CD4+ T cells in Th1 and Th17 polarizing conditions in the presence of C2 or C3. Effector 
T cell differentiation into Th1 or Th17 cells were increased by C2 or C3 in a dose-






signature genes of Th1 or Th17 cell by SCFAs. Both C2 and C3 elevated the expression 
levels of IL-17A, IL-17F, ROR RORt, T-bet, and IFNat mRNA level (Fig. 2.2A). 
Regulation of transcription factors by SCFAs was further verified in various T cell-
activating conditions. Naïve CD4+ T cells were activated with standard anti-CD3 (5μg/ml) 
or low anti-CD3 (1 μg/ml) in the presence of C2 or C2, and expressions of RORt, T-bet, 
and FoxP3 were determined. While C2 and C3 increased frequencies of RORt+ and T-bet+ 
cells, FoxP3+ cells were unaffected (Fig. 2.2B). However, FoxP3 expression combined 
with RORt was enhanced by C2 or C3 in a weak anti-CD3 (1 g/ml) activation condition 
(Fig. 2.3). 
To investigate the function of SCFA-induced effector T cells, we examined the 
colitis-inducing activity of T cells. We cultured Th17 cells in the presence or absence of 
C2 (C2-Th17 or Th17 cells) (Fig. 2.4A) and transferred cultured T cells into Rag1-deficient 
mice. Unexpectedly, the control Th17 cell-injected mice started to lose more weight 15 
days after administration. Despite a higher frequency of IL-17+ T cells, C2-Th17 cells were 
unable to induce colitis as severely as control Th17 cells (Fig. 2.4). In line with low anti-
CD3 activation conditions (Fig. 2.3B), the increased frequency of FoxP3+ T cells was 
observed in the colon of the mice injected with C2-treated T cells (Fig. 2.4C). Additionally, 
we examined the function of C2-treated Th1 cells in colitis. Similar to Th17 cells, cultured 
Th1 cells induced less inflammation despite increased IFNγ+ T cell frequencies (Fig. 2.5). 
These results indicate that C2-treated T cells have anti-inflammatory functions in vivo; 
however their inflammatory cytokine expressions and transcription factors are promoted 







C2 and C3 promote IL-10-producing regulatory T cells 
Because C2-promoted effector T cells were not inflammatory, we asked to 
determine the factor that regulates inflammation. To answer this question, we performed a 
microarray analysis. Gene expressions in Th17 and Th1 cells were compared in the 
presence and absence of C2. Among a number of genes that are regulated by C2 treatment, 
we found IL-10 expression was consistently upregulated by C2 in both Th17 and Th1 cells 
(Fig. 2.6).  This led us to investigate the differentiation of naïve CD4+ T cells into IL-10+ 
T cells in response to SCFAs. We cultured naïve T cells in Tnp, Th1, and Th17 polarizing 
conditions with SCFAs. With each condition, IL-10+ T cells expanded as in a SCFA-dose 
dependent manner. In addition, C2 or C3 increased T cell subsets that express both IL-10 
and IFNγ (Fig. 2.7 A and B). Upregulated IL-10 secretion by SCFAs in culture media was 
verified at protein level with ELISA and at mRNA level by qRT-PCR (Fig. 2.7 C and D). 
Although it has been reported that SCFAs enhance both IL-10+ and FoxP3+ T cells (29, 31), 
we were unable to reproduce SCFA-dependent IL-10+ FoxP3+ T cell increase by standard 
anti-CD3 (5 μg/ml) activation. However, those subsets were expanded by low anti-CD3 (1 
μg/ml) activation (Fig. 2.8).    
SCFAs stimulated both effector and regulatory T cell differentiation, and these cells 
showed anti-inflammatory function in a colitis model. To examine the regulatory activity 
of SCFAs in T cells, we performed an in vitro suppression assay. When we cultured 
activated T cells with CSFE-labeled CD4+CD25- T cells, C2-treated T cells suppressed the 
proliferation of responder T cells more efficiently than control-T cells. However, C2-
treated T cells from IL10-deficient mice did not show suppressed activity (Fig 2.9). This 






So far, we examined the effect of SCFA on CD4+ T cells. Next, we asked if other 
T cells, such as CD8+ T cells have similar responses to SCFAs. When we cultured CD8+ T 
cells with SCFAs, we found that IL-10, IFN, and IL-17 expressions were also significantly 
increased in both Tc1 and Tc17 polarizing conditions (Fig. 2.10). 
Then, we investigated the impact of SCFAs in vivo by providing C2-containing 
water to mice. First, we examined the concentration of the major SCFA-C2, C3, and C4- 
in intestinal tissues and cecal contents. C2 administration significantly increased C2 
concentration in cecal contents and colon tissues, whereas the effect on C3 and C4 
concentrations was minimal (Fig. 2.11). In line with increased concentration, C2 feeding 
increased the frequency of IL-10+ T cells in cecum, while it did not affect cells in secondary 
lymph nodes (Fig 2.12). We previously reported the impact of C2 feeding on the clearance 
of C. rodentium (38). To examine the regulation of C2 on T cells in bacteria infected 
conditions, we evaluated the change of effector T cells following C2 feeding. Frequencies 
of Th1 and Th17 cells were elevated in secondary lymph nodes as well as in cecum, but 
IL-10+ T cells were consistent (Fig 2.12). These results explain the dual roles of SCFAs in 
T cell differentiation. In a steady state, SCFAs promote regulatory T cells but boost effector 
T cells and enhance immunity in bacteria infected conditions.  
Because SCFAs promote different T cell subsets depending on immune stimulation, 
we applied an anti-CD3 injection (i.p.) model, which induces inflammation in the intestine 
and increases IL-10+ T cells (84, 85). In systemic organs, such as the spleen and MLN, 
both IL-10+ T cells and effector T cells were expanded via C2 administration. In the 
intestinal tissues, C2 did not stimulate the frequency and number of IL-10+ and effector T 






anti-CD3 induced inflammation in terminal ileum in an IL-10 dependent manner (Fig 2.13 
D). 
 
The SCFA effect on T cells is independent of GPR41 or GPR43 
To define the role of GPRs in SCFA-promoted T cell differentiation, first we 
compared the expression levels of GPR41 and GPR43 between T cells and non-T cells. 
Cultured T cells or isolated T cells from fresh colons or spleens showed minimal 
expressions of Gpr41 and Gpr43 at mRNA level compared to colonic epithelial cells, and 
Gr+ cells (Fig 2.14). To investigate if GPRs are required for SCFA-enhanced T cell 
differentiation, we prepared naïve CD4+ T cells from GPR41-and GPR43-deficient mice, 
then cultured in the presence of C2 or C3. Deficiency of GPR41 and GPR43 in the T cells 
did not affect SCFAs-enhanced Th1, Th17 or IL-10+ T cell differentiation (Fig 2.15). Next, 
we examined the role of GPR41 and GPR43 in T cell regulation in vivo. Compared to WT 
mice, frequencies of IL-17+, IFN+, and IL-10+ T cells in GPR-deficient mice were not 
significantly changed in the spleen, MLN, or colon tissues (Fig 2.16). We further examined 
effector and IL-10+ T cell changes by C2-feedingin GPR41- and GPR43-deficient mice. 
C2 administration promoted frequencies and cell numbers in the colon tissues of both WT 
and GPR-deficient mice (Fig 2.17). These data suggest that GPR41 and GPR43 expressions 
are not required for SCFA-dependent T cell differentiation. 
 
SCFAs inhibit HDACs and increase mTOR pathway in T cells 
SCFAs are known as histone deacetylases (HDAC) inhibitors and SCFA-mediated 






that HDAC activity could be regulated in a GPR43-dependent manner, although the direct 
action of SCFA on T cells was not demonstrated (88). To verify if SCFAs directly affect 
HDAC activity in T cells, we performed a cell-based HDAC assay, which is designed for 
SCFAs to enter T cells and inhibit HDAC activity. We compared HDAC activity to SCFAs 
in activated T cells from WT-, GPR41-, and GPR43-deficient mice. HDAC activity 
gradually declined as higher concentrations of SCFAs were applied. Interestingly, SCFAs-
mediated HDAC inhibition was not influenced by GPR41 or GPR43 expression (Fig. 2.18). 
Since we verified that SCFAs suppress HDAC activity in T cells, we asked if SCFAs 
upregulate T cell differentiation via HDAC inhibition. We compared the effect of SCFAs 
on T cell differentiation to TSA, a class HDAC I and II inhibitor. Similar to C2 or C3, TSA 
promoted both effector and IL-10+ T cell differentiation in each polarizing condition (Fig. 
2.19).  
mTOR-signaling activation is required for not only cellular metabolism, but also 
for effector or IL-10+ T cell differentiation (89-91).  Because both SCFAs and TSA affected 
T cell differentiation, we examined their effect on mTOR activity. When CD4+ T cells were 
activated with SCFAs or TSA, phosphorylation levels of ribosomal protein S6 (rS6), a 
major target of the mTOR pathway, was increased (Fig 2.20A). Thus, we found that C2 
and C3 maintain mTOR activity up to 60 hours and promote mTOR activity in a dose-
dependent manner (Fig. 2.20 B). To confirm if SCFA-induced mTOR activity opens doors 
to T cell differentiation, we inhibited the mTOR pathway with rapamycin (an mTOR 
inhibitor) and examined if SCFAs were still able to increase IL-10+ T cell induction. 
Rapamycin effectively suppressed the frequency and number of effector and IL-10+ T cells 






mediated mTOR activity on T cell differentiation was also verified with AMP kinase 
(AMPK) activity in T cells. AMPK is involved in cellular metabolism and suppresses 
mTOR pathways (92-94). We cultured T cells with C2 or C3 in the presence of an AMPK 
activator, metformin. Metformin treatment, which can suppress mTOR pathways, 
abolished SCFAs-dependent IL-10+ T cell increases (Fig. 2.22).  
So far, we have investigated the role of C2 and C3 in T cell regulation. Butyrate 
(C4) is another major SCFA and well recognized as a HDAC inhibitor. We asked if C4 has 
comparable effects on mTOR activity and T cell differentiation as C2 or C3. C4 promoted 
mTOR activity and T cell differentiation in dose-dependent manners (Fig. 2.23). 
The importance of HDAC inhibition and mTOR activation in SCFA-mediated T 
cell differentiation was examined. We further investigated the involvement of HDAC 
inhibition and mTOR pathway. rS6 is a substrate of S6 kinase (S6K) and one study reported 
that TSA treatment induced the acetylation of S6K (95).  We found that C2, C3, and TSA 
facilitated acetylation of S6K in activated T cells (Fig 2.24). Comprehensively, these 
results demonstrate the intracellular mechanisms of SCFA-dependent T cell differentiation. 
SCFAs regulate mTOR activity and HDAC inhibition in T cells, which lead to the 
acetylation of S6K.   
 
SCFAs also regulate mTOR-related intracellular pathways in T cells 
Activated mTOR pathway promotes IL-10 expression through signal transducer 
and activator of transcription 3 (STAT3) (96). C2 or C3 enhanced phosphorylation of 






did not change the activity of extracellular signal-regulated kinase (ERK) pathways (Fig. 




We report the role of gut metabolites SCFAs in T cell differentiation and T cell-
dependent intestinal inflammation. Major SCFAs, C2, C3, and C4 directly support naïve T 
cell differentiation into both effector and regulatory T cells. They showed regulatory 
function and anti-inflammatory effects. The action of SCFAs is not dependent on their 
receptors, GPR41 or GPR43. Rather, SCFAs directly induced mTOR activation and HDAC 
inhibition in T cell differentiation. In particular, SCFAs promoted acetylation of the 
mTOR-S6K molecule. Besides, downstream pathways of mTOR activation were also 
enhanced by SCFAs. 
SCFAs are generated by microbial fermentation in the gut. GPR41 or GPR43 are 
major SCFA receptors. SCFAs activate these receptors and regulate various immune 
responses. However, the role of GPR41 or GPR43 is intriguing because their expressions 
are variable in different cell types. In our study, we demonstrated the minimal expression 
of GPR41 and GPR43 in both splenic and colonic T cells. SCFA-mediated T cell 
differentiation was independent of GPR41 and GPR43 in vitro and in vivo.  
Instead, we discovered the intracellular mechanisms of SCFA influence on T cell 
differentiation. Activation of mTOR pathways is required for effector and IL10+ T cell 
differentiation (96). Accordingly, we found that SCFAs promoted mTOR activity in 






rapamycin or AMPK activator abolished the effect of SCFAs on T cell differentiation. 
STAT3 signaling is downstream of mTOR pathways and their activation modulates 
effector and IL-10+ T cell generation (98, 99). In this regard, we examined STAT3 
activation and glucose uptake levels in SCFA-treated T cells. C2 and C3 enhanced STAT3 
phosphorylation. Histone acetylation regulates gene transcription and determines the 
function of T cells (100). SCFAs are HDAC inhibitors, and recent studies reported that 
SCFA-mediated HDAC inhibition promotes regulatory T cell expansion (29-31). In this 
study, we examined the effect of SCFAs on HDAC activity in activated T cells. We found 
that C2, C3, and C4 directly inhibited HDAC activity in a GPR41- and GPR43-independent 
manner. C2 and C3 showed comparable effect on effector or IL-10+ T cell differentiation 
as TSA, a HDAC I and II inhibitor. So far, we have showed that SCFAs regulate T cell 
differentiation through two intracellular pathways, mTOR activation and HDAC inhibition. 
In order to fill the gap between the suggested mechanisms, we validated that SCFAs 
enhance mTOR-S6K acetylation, which can be a regulatory point of T cell differentiation.  
It has been thought that SCFAs mainly affect regulatory T cell differentiation and 
anti-inflammatory cytokine expression (29-31).  A compelling observation was that SCFA- 
induced amixed T cells express both regulatory and effector cytokines. SCFA-treated T 
cells alleviated colitis and suppressed other T cell proliferation. Our results imply that 
SCFAs regulate T cell differentiation by immunological stimulation and cytokine milieu. 
In mice, SCFA administration augmented IL-10+ T cells in regular conditions. Upon anti-
CD3 stimulation or bacterial infection, however, effector T cells expanded but regulatory 






cell differentiation. In a weaker TCR-activation conditions, SCFAs induced more FoxP3+ 
T cells. 
Our study emphasizes the importance of gut metabolites in the immune system and 
homeostasis. SCFAs, major gut bacterial products, control adaptive immunity by 
regulating T cell differentiation.  These results also provide an example of how the host 
immune system harnesses commensal bacterial metabolites for the induction of specialized 
effector and regulatory T cells. Hence, SCFA levels and the immunological context control 
T cell differentiation. Overall, this study has many practical ramifications in the regulation 
of tissue inflammation and immunity. 
 
2.5 Summary and future directions 
 
2.5.1 Summary 
We investigated the impact of SCFAs on T cell regulation and T cell mediated 
inflammation and immunity. SCFAs promote both effector and regulatory T cells. In vitro 
and in vivo studies revealed that SCFA-induced T cell has suppressive activity on 
responder T cells and ameliorated T cell-mediated colitis. In addition, SCFA administration 
enhanced Th17 cell response to C. rodentium infection and efficiently cleared invading 
pathogens. Interestingly, indicated functions of SCFAs were GPR41- and GPR43- 
independent. In splenic or colonic T cells, gene expressions of these receptors were rarely 
detectable. SCFAs are known as HDAC inhibitors and we demonstrated that SCFAs 
suppressed HDAC activity in T cells. SCFAs increased the phosphorylation of rS6, which 






2.5.2 Future direction 
 
The more intricate mechanism by which SCFAs regulate mTOR or HDAC activity 
in T cell need to be studied. First, we will examine how SCFAs regulate mTOR activity. 
AMPK activation is known to block mTOR pathways and affect T cell differentiation (92), 
and we demonstrated that the AMPK activator metformin inhibited SCFA-mediated IL-
10+ T cell induction. To verify the effect of SCFAs on mTOR upstream molecules, we will 
examine the AMPK activity level in SCFA-treated T cells. In the case that AMPK activity 
is suppressed by SCFA, we will further examine if SCFAs control AMPK upstream signal.  
The liver kinase B1 (LKB1) is a serine/threonine kinase that signals for AMPK activation 
and control T cell regulation (101). We will first measure mRNA and protein expression 
of  LKB1 in SCFA-treated T cells. Then, we will culture T cell with LKB1-siRNA in the 
presence or absence of SCFAs (102), and examine whether SCFAs-induced mTOR 
activation or IL-10+ T cells. 
Next, we will ask how SCFAs regulate HDAC activity in T cells. We found that 
theHat1 gene was upregulated by SCFAs in different T cell polarized condition by 
microarray analysis (data not shown). HAT represses HDAC activity (103), and we will 
examine if SCFAs enhance histone acetylation via HAT activation. We will utilize a HAT 
activity assay kit that detects NADH, released by HAT activated conditions. Next we will 
ask if SCFA-induced HAT activity regulates IL-10 producing T cells. Among several co-
activators of HATs, CBP and p300 induce hyper-acetylation in histone N-terminal tail 
lysine in T cells. We will investigate the role of SCFAs in p300 mediated IL-10 expression 






with the IL-10 promotor gene inserted reporter plasmid (pGL4.10-IL10) into naive T cell 
or T cell lines. Transfected cells will be cultured in the presence of SCFAs and IL-10 




















Figure 2.1 Effect of Short chain fatty acids (SCFAs) on effector T cell (Th17 and 
Th1 cells) differentiation in a dose dependent manner. 
Major SCFAs acetate (C2) and propionate (C3) promoted naïve CD4+ T cell differentiation 
into Th17 and Th1 cells. Naïve T cells were isolated and activated with anti-CD3/CD28 in 
the presence of various concentrations of C2 or C3. Th17 cell differentiation was 
determined after a five or six day culture with IL-1β, IL-6, IL-21, IL23, TGFβ1, anti-IL-4 
and anti-IFNγ. Th1 cell differentiation was determined after five or six day culture in Th1 
conditions (IL-12, IL-2, and anti-IL-4). *Significant differences resulted from blank groups 









Figure 2.2 Regulation of signature genes and transcription factors by SCFAs in 
Th17 and Th1 cells. 
(A) mRNA expression level of selected genes and transcription factors were determined 
by quantitative real-time PCR.  Naïve T cells were isolated and cultured with SCFAs for 3 
days in Th17- or Th1-polarizing conditions. (B) Expression of FoxP3, RoRγt, and T-bet 
were examined in Th17 or Th1 cells. Naïve T cells were cultured with C2 or C3 for five or 








Figure 2.3 FoxP3 expression in T-bet+ or RORγt+ T cells with a weak anti-CD3 (1 
μg/ml) activation. 
Naïve T cells were cultured in Th-1 or Th17-polarized conditions for five or six days. Cell 
were activated with a low dose of anti-CD3 (1 μg/ml) in combination with C2 (10 mM) or 
C3 (1 mM). Frequencies of FoxP3+ in T-bet+ T cells (A) or RORγt+ cells (B) were 
determined. Representative or pooled data of three experiments are shown. *Significant 










Figure 2.4 Role of SCFA-treated Th17 cells in T cell-mediated colitis. 
(A) Phenotype of injected Th17 cells and body weight changes in host mice. Naïve T cells 
were cultured with C2 in Th17 condition for five or six days. (B) Histological changes in 
the distal colon were determined by HnE staining (x 100 original magnification; scale bar 
= 200 μm). (C) Frequencies of T cell subsets (Th1, Th17 and FoxP3+ T cells) were 
examined in the distal colon by flow cytometry. Representative or pooled data from two or 
three experiments are shown (n=5-10 for A, B, or C). *Significant differences from 











Figure 2.5 Role of SCFA treated Th1cell in T cell-mediated colitis. 
(A) Phenotype of injected Th1 cells and body weight changes in host mice. Naïve T cells 
were cultured with C2 in Th1 condition for five or six days.  (B) Histological changes in 
distal colon were determined by HnE staining (x 100 original magnification; scale bar = 
200 μm). (C) Frequencies of T cell subtypes (Th1, Th17 and FoxP3+ T cells) were 
examined in the distal colon by flow cytometry. Representative or pooled data from two or 
three experiments are shown (n=4-7 for A, B, or C). *Significant differences from indicated 












Figure 2.6 SCFA-mediated gene expression in T cells. 
Microarray analysis identified genes that are regulated by SCFAs. Naïve T cells were 
isolated and cultured with C2 for three days in Th17 or Th1 polarizing conditions. Data 










Figure 2.7Effect of SCFAs on IL-10 expression in T cells. 
(A) Changes in cytokine expressions were determined by flow cytometry. Naïve CD4+ T 
cells were cultured with SCFAs in Tnp, Th17, and Th1 conditions. (B) SCFA-induced IL-
10 expression in each T cell subset in a dose dependent manner. Secreted IL-10 was 
examined using a conditioned media by ELISA (C), and IL-10 mRNA level was 
determined by quantitative real-time PCR (D). *Significant differences from blank groups 













Figure 2.8 SCFA-enhanced FoxP3+ and IL10+ T cells. 
Naïve T cells were cultured in Tnp (A), Th1 (B), or Th17 (C) polarized conditions for five 
to six days. Cell were activated with two different doses of anti-CD3 (1 and 5 μg/ml) in the 
presence of C2 (10 mM) or C3 (1 mM). Frequencies of FoxP3+ and IL-10+ T cells were 
determined by flow cytometry. Representative or pooled data of the three experiments are 







Figure 2.9 Suppressive functions of SCFA-enhanced IL-10 in T cell proliferation. 
CD4+ T cells were isolated from WT or IL10-deficient mice and cultured in the presence 
or absence of C2 in Th1 polarizing condition. C2-treated suppressor T cells were co-
cultured with responder cells (CFSE-labeled CD4+CD25- T cells) for three days. 
Suppressive activity of C2-treated T cells was evaluated by flow cytometry. *Significant 
















Figure 2.10 SCFA-enhanced IL-10 in CD8+ T cells. 
Total CD8+ T cells were isolated and cultured with C2 (10 mM) or C3 (1 mM) in Tc1 (IL-
2, IL-12, and anti-IL-4) or Tc17 (IL-1β, IL-6, IL-21, IL23, TGFβ1, anti-IL-4 and anti-IFNγ) 
polarizing conditions. After a five or six day culture, frequencies of IL-10, IL-17, or IFNγ+ 
cells were determined with flow cytometry. *Significant differences from blank groups or 
















Figure 2.11 Changes of SCFA concentrations in cecal contents and intestinal tissues 
by C2 feeding. 
Mice were administered C2-infused (200 mM) drinking water. The cecal material, jejunum, 
and colon tissues were collected from C2-fed or control mice. Concentrations of C2, C3, 
and C4 were determined by liquid chromatography-mass spectrometry. *Significant 













Figure 2.12 The distinct effect of SCFAs on effector or IL-10+ T cells from a 
bacterial infection. 
Mice were fed normal or C2-containing water. Indicated mice were infected with 
Citrobacter rodentium. Changes of Th1, Th17 and IL-10+ T cells were examined in the 
spleen, MLN, or cecum by flow cytometry fourteen days of post infection. (A) Pooled data 
(n=7-9) or (B) representative dot plots are shown. *Significant differences between 







Figure 2.13 Anti-inflammatory role of SCFAs in anti-CD3 induced colitis. 
Mice were fed normal or C2-containing water, followed by an anti-CD3 antibody (145-
2C11) injection. Mice were euthanized 52 hours later and frequencies or numbers of IL-
10+ T cells (A), Th17 cells (B), or Th1 cells (C) were determined by flow cytometry (n=6-
9/group). (D) Inflammation severity was compared between WT and IL10-deficient mice 
after anti-CD3 injection and C2 feeding. *Significant differences from regular water fed 







Figure 2.14 Expression of SCFA receptors, GPR41 and GPR43 in T cells and other 
subtypes. 
Cultured or splenic CD4+ T cells, colonic epithelial cells (CD326+), CD4+ or CD4- T cells 
of colon, bone marrow Gr1+cells, and cultured BM-DCs were prepared from WT-, GPR41-, 
or GPR43-deficient mice. mRNA levels of GPR41 or GPR43 was determined by 















Figure 2.15 SCFA-promoted T cell differentiations in GPR41- or GPR43-deficient 
CD4+ T cells. 
Naïve CD4+ T cells were isolated from WT, GPR41-, or GPR43-deficient mice and 
cultured in Th1 or Th17 polarizing conditions in the presence of C2 or C3. After five to six 
days of culture, frequencies of IL-10, IL-17, or IFNγ+ cells were determined by flow 
cytometry. Representative dot plots (A) and pooled data from three individual experiments 














Figure 2.16 Normal population of effector and IL-10+ T cells in GPR41- and 
GPR43-deficient mice. 
WT-, GPR41-, and GPR43-deficient mice of six to nine weeks of age were prepared and 
cells were collected from indicated organs. Frequencies of Th17, Th1, or IL-10+ T cells 
were shown from WT- and GPR-deficient mice. *Significant differences from WT 
















Figure 2.17 Induction of IL-10+ T cells in SCFA-fed WT-, GPR41-, and GPR43-
deficient mice. 
WT-, GPR41-, and GPR43-deficient mice were given C2-containing water for six to eight 
weeks and colonic cells were collected. Frequencies and numbers of Th1 (A), Th17 (B) or 
IL-10+ T cells (C) were shown in WT and GPR-deficient mice. Pooled data (n=7-10) are 

















Figure 2.18 Inhibition of histone deacetylases (HDACs) by SCFAs in GPR41- and 
GPR43-independent manners. 
Cell-based HDAC activity by SCFAs was measured in WT, GPR41-, and GPR43-deficient 
T cells. Naïve CD4+T cells were cultured for two days, followed by additional incubation 
with SCFAs or trichostatin A (TSA) for two hours, and assayed for the HDAC activity. 

















Figure 2.19 Comparison of SCFAs and TSA in regulating T cell differentiation. 
Naïve CD4+ T cells were cultured in Tnp, Th1 or Th17 polarizing conditions in the 
presence of SCFAs or TSA. After a five to six day culture, frequencies of IL-10, IL-17, or 
IFNγ+ T cells were examined by flow cytometry. Representative dot plots (A) and pooled 
data from three individual experiments are shown (B). *Significant differences from blank 







Figure 2.20 SCFA-mediated mTOR activity in T cells. 
(A) T cells were activated with anti-CD3/CD28 for three days in the presence of SCFAs or 
TSA. For mTOR activity, the phosphorylation of rS6 was evaluated. (B) Kinetics (0-60 
hours) of mTOR activity (left) and SCFA dose-dependent mTOR activity (right) in T cells 











Figure 2.21 Effect of mTOR inhibition on SCFA-promoted T cell differentiation. 
Naïve CD4+ T cells were cultured in Tnp, Th1 or Th17 polarizing conditions in the 
presence of SCFAs and rapamycin (25 nM). After a five to six day culture, frequencies (A) 
and cell numbers (B) of IL-10, IL-17, or IFNγ+ T cells were examined by flow cytometry. 
(C) Secreted IL-10 from cultured media was determined by an enzyme-linked 
immunosorbent assay (ELISA) assay. Pooled data from at least three different experiments 








Figure 2.22 Effect of AMPK activation on SCFA-promoted T cell differentiation. 
Naïve CD4+ T cells were cultured for five to six days in Th1 or Th17 polarizing conditions 
in the presence of SCFAs and metformin (1mM). Changes in frequencies of IL-10+IFNγ+ 
cells and IL-17+ T cells were examined by flow cytometry. Representative and pooled data 
are shown from at least three different experiments. *Significant differences from blank 








Figure 2.23 Butyrate (C4) effect on mTOR activity and T cell differentiation. 
Naïve CD4+ T cells were activated with aCD3/CD28 in Tnp conditions for three days (A) 
or five to six days (B) with indicated concentrations of C4. (A) mTOR activity in T cells 
was examined with antibody to rS6 phosphorylation. (B) T cell differentiation in Tnp, Th1, 
and Th17 polarizing conditions was determined by flow cytometry. Representative and 
pooled data from three different experiments are shown. *Significant differences from 











Figure 2.24 SCFA-mediated acetylation of S6K in T cell. 
T cell lysates were prepared after three-day activation with anti-CD3/CD28 in the presence 
of SCFAs or TSA. The lysates were precipitated with an anti-acetylated lysine antibody. 
To evaluate the acetylation of S6K, immunoprecipitates of acetylated lysine were 
incubated with an anti-S6K antibody and detected with the western blotting method (upper). 
In addition, the S6K activity in the total cells were determined (lower). Representative data 














Figure 2.25 Effect of SCFAs on STAT3 activation in T cells. 
Naïve CD4+ T cells were activated with aCD3/CD28 and hIL-2 in the presence of SCFAs. 
After three days, antibody to phosphorylation of STAT3 was used and determined the 
activity of STAT3 by flow cytometry. Representative and pooled data from at least three 
















Figure 2.26 Effect of SCFAs on ERK activation in T cells. 
Naïve CD4+ T cells were activated with aCD3/CD28 in the presence of SCFAs for one 
hour (A) or three hours (B). After the activation, an antibody to phosphorylation of MAPK 
(Erk1/2) was applied and examined the activity of ERK pathways by flow cytometry.  
Representative and pooled data from three different experiments are shown. *Significant 













Figure 2.27 Regulation of SCFAs during T cell differentiation and underlying 
intracellular mechanisms. 
SCFAs promote both regulatory and effector T cells differentiation. These cells have either 
anti-inflammatory function or support host immunity. SCFAs directly activate mTOR 











CHAPTER 3. PROLONGED EXPOSURE TO SHORT CHAIN FATTY ACIDS 




Intestinal microbiota is critical to maintaining the homeostasis of the intestines as 
well as other peripheral organs. Bacterial composition is changed by dietary ingredient and 
affects gut barrier function. In symbiotic conditions, beneficial metabolites such as SCFAs 
are produced and support epithelial integrity. SCFAs also provide energy sources and 
regulate immune responses in SCFA receptor-dependent or independent manners. On the 
other hand, pathobiont-producing metabolites exacerbate inflammation 
In T cells, the expression of SCFAs receptors G protein-coupled receptors (GPCRs), 
is minimal. Hence, SCFAs inhibit histone deacetylase (HDAC) and activate mTOR 
pathways that control of T cell regulation. Environmental factors, such as infection or 
inflammation, direct SCFAs to induce effector or regulatory T cells. In the case of a 
bacterial infection, SCFAs promote host immunity by increasing effector T cell that fight 
invading pathogens. Besides, SCFAs expand colonic regulatory T cells in inflammatory 
conditions. While intestinal SCFA actions are well established, the role of SCFAs in the 
renal system has not been clearly determined. For this reason, we treated mice with water 







Unexpectedly, SCFAs feedings for four weeks or longer induced ureteral obstruction and 
hydronephrosis. We found that T cells and gut microbiota were required for disease 
development. mTOR pathway was activated in affected mice and the SCFA-induced 
disease was prevented by the mTOR inhibitor treatment. Results suggest that prolonged 
exposure to SCFAs has the potential to develop renal inflammation.    
 
3.2 Materials &Methods 
 
Mice and treatments 
C57BL/6 mice (originally from Harlan, Indianapolis, IN), Gpr41(-/-) mice 
(provided by M. Yanagisawa, UT Southwestern Medical Center at Dallas), Gpr43(-/-) mice 
(Deltagen, San Mateo, CA), and TCRβ-deficient mice (B6.129P2-Tcrbtm1Mom/J, The 
Jackson Laboratory) were kept at Purdue for at least 12 months before use. Mice were 
treated with sodium acetate (C2 at 100, 150, or 200 mM, pH 7.5), sodium propionate (C3 
at 200 mM, pH 7.5), or sodium butyrate (C4 at 200 mM, pH 7.5) in drinking water from 3 
or 32 weeks of age for 2-6 weeks. In the indicated groups, mice were fed with rapamycin 
(25 μg/ml, LC laboratories) and/or vancomycin (0.5 g/L) in drinking water for same time 
periods in the presence of SCFAs. Based upon hydronephrosis in the kidney mice were 
diagnosed as C2RD. For most of the experiments, male mice were used unless indicated 
as female. For the neutralization of cytokines, antibodies to IL-17A (clone 17F3, BioXcell) 







for 6 weeks. All animal experiments were approved by the Purdue Animal Care and Use 
Committee (PACUC). 
 
Confocal microscopy and histology 
Frozen sections of kidneys or ureters (8 μm) were prepared with Leica CM1860 
Cryostat fixed with acetone. Sections were stained with antibody to collagen type IV 
(rabbit polyclonal antibody) and then stained with fluorescently labeled polyclonal anti-
rabbit IgG antibodies and antibodies to CD4 (clone RM4-5), CD11c (clone N418), Gr-1 
(clone RB6-8C5), cytokeratin (clone AE1/AE3), and muscle actin (clone HHF35). 
Fluorescent confocal images of kidney and ureter sections were acquired with a Leica SP5 
II laser scanning confocal microscope. For histological analysis, paraffin tissue sections (8 
μm) were stained with hematoxylin and eosin. 
 
Analysis of serum and urine 
Level of creatinine in serum or urine was determined as described before (104). 
Briefly, 1 ml of creatinine assay solution was prepared with picric acid, sodium hydroxide, 
and EDTA disodium salt. The assay buffer was mixed with 0.1 ml of standard solutions, 
serum, or urine. After 30 and 90 seconds, the absorbance was measured at 492 nm. To 
measure the concentration of urea, a mixture of acid solution (200 μl, H2SO4, H3PO4, and 
H2O in a ratio of 1:3:7) and 9% alpha-isonitrosopropiophenon solution (10 μl) was reacted 







measured at 540 nm. Concentrations of creatinine and urea were calculated based on the 
absorbance values of standard solutions. 
 
Blood pressure measurement 
Systolic and diastolic blood pressures were non-invasively measured by 
determining the tail blood volume with a volume pressure recording sensor and an 
occlusion tail-cuff (CODA System, Kent Scientific, Torrington, CT) (105). Maximum cuff 
pressure was set to 250 mmHg, with 20 seconds for each inflation run, per the 
manufacturer’s recommendations. Each mouse was measured 20 times and averages of all 
accepted runs were used.  
 
Cell culture and differentiation in vitro 
Total cells from renal draining lymph nodes were collected and digested with 
collagenase type 3 (Worthington Biochemical, Lakewood NJ) at 37oC for 30 min. Cells 
were activated with coated anti-CD3 (5 μg/ml, clone 145-2C11) in different T cell 
polarizing conditions: hIL-2 (100 U/ml) for a Tnp condition;  hIL-2, mIL-12 (1 ng/ml), and 
anti–mIL4 (clone 11B11, 10 μg/ml) for a Th1 condition; hTGF-β1 (5 ng/ml), mIL-6 (20 
ng/ml), mIL-1β (10 ng/ml), mIL-23 (10 ng/ml), mIL-21(10 ng/ml), mTNF-α (20 ng/ml), 
anti-mIL-4 (10 µg/ml, clone 11B11), and anti-mIFNγ (10 µg/ml, clone XMG1.2) for a 







and/or rapamycin (25 nM, Enzo). mTOR activation or cytokine expression was determined 
after 3 or 5 days respectively.  
 
Flow cytometry 
Kidney or ureter tissues were digested with collagenase type 3 for 1 hour and the 
total cells were collected. For intracellular staining, surface antigen of CD4 was stained 
and cells were activated with RPMI 1640 (10% FBS) with 12-myristate 13-acetate (50 
ng/ml), ionomycin (1 μM), and monensin (2 mM) for 4 hours followed by fixation and 
permeabilization. Antibodies to IL-10 (clone JES5-16E3), IL-17A (clone TC11-18H10.1), 
IFNγ (clone XMG1.2) and/or anti-FoxP3 (clone FJK-16s) was applied for intracellular 
staining. To determine the level of rS6 protein phosphorylation, antibody to phosphorylated 
rS6 (clone Ser235/236; D57.2.2E) was applied. The frequencies of T helper cells were 
determined from the total lymphocyte and CD4+ gates. The total cell numbers were 
calculated from frequencies of each cell population and numbers of retrieved cells from 
each organ (1 spleen, 2 draining lymph nodes, 1 kidney, and 2 ureters).  
 
Measurements of SCFA levels in kidney tissues 
100mg of kidney tissues were mixed and homogenized in 900 µl of water using 1.4 
mm ceramic beads and Precellys®24 homogenizer. Supernatant of homogenates or SCFAs 







LC/MS System (Agilent Technologies) as described before (106). Ratio between internal 
and external standards were used to calculate SCFA concentrations in kidney tissues.   
 
Microarray analysis 
Total RNA was prepared from normal or C2RD kidneys and microarray study was 
assessed by Mouse 430 2.0 chips (Affymetrix, Inc.). Analysis of the gene pattern was 
processed as described previously (83). The microarray data have been deposited in the 
GEO database (accession number: GSE69864). For a visualization of the gene expression 
pattern, the GenePattern genomic analysis platform 
(www.broad.mit.edu/cancer/software/genepattern), Cluster 3.0, and TreeView 1.6 (Eisen 
Lab, rana.lbl.gov/EisenSoftware.htm) were utilized. Microarray data of C2RD was 
compared to the published gene expression. We reclaimed published data from the GEO 
site: GSE36496 (UUO), GSE48041 (Mgb-/-), GSE12024 (Lupus), and GSE24352 (PKD). 
For conversion of Gene IDs from different microarray plat forms into Agilent ID, DAVID 
Bioinformatics Resources 6.7 (http://david.abcc.ncifcrf.gov) was utilized.  
 
Quantitative real-time PCR 
Using TRIzol® solution (Invitrogen), total RNA was extracted and cDNA was 
synthesized with SuperScript® II Reverse Transcriptase (Invitrogen). Quantitative real-
time PCR (qRT-PCR) was performed with Maxima® SYBR Green/ROX qPCR Master 
Mix (Thermo Scientific).   











Il17a (GAC.TCT.CCA.CCG.CAA.TG and CGG.GTC.TCT.GTT.TAG.GCT);  
Ifng (AGA.CAA.TCA.GGC.CAT.CAG.CA and CGA.ATC.AGC.AGC.GAC.TCC.TTT); 
Tgfb1(CGC.CAT.CTA.TGA.GAA.AAC.C and GTA.ACG.CCA.GGA.ATT.GT); 
Ccl2 (AAG.ATG.TGC.TGG.ACA.GCT.G and TCC.AGG.GCA.CAT.ATG.CAG.AG);   
Ccl5 (GCG.GGT.ACC.ATG.AAG.ATC.TC and CAG.GGT.CAG.AAT.CAA.ACC.CT); 





Ccr5 (CCT.CCT.GAC.AAT.TGA.TAG.GTA.C and 
ATG.ATG.GCA.AAG.ATG.AGC.CTC.A); 








Gpr41 (CTG.GCT.GTT.GTG.ACG.CTT and CGG.TGA.CAA.ATT.CAG.AAC.TCT); 
Gpr43 (CTT.CTT.GCA.GCC.ACA.CTG.CT and CAC.TCC.TTG.GAT.GGC.TCT.TC); 
The expression levels of genes were normalized by the β-actin levels.  
 
Bacterial DNA analysis 
To examine the composition of gut bacteria, cecal content were collected from 
control or C2RD mice. Bacterial DNA was isolated using a FastDNA® SPIN Kit (MP 
Biomedicals) according to the manufacturer’s protocol. For qPCR, primers were designed 
according to previous publications (107, 108). Differences (ΔCT) between cycle threshold 
(CT) values of eubacteria and each bacterial group were calculated (2
-ΔCT). Relative 
expression of bacterial groups in C2RD was compared to the control groups.  
 
Statistical analysis 
Student’s t test (1 or 2-tailed) or the Mann-Whitney test were used to determine the 





Oral administration of C2 induces progressing renal disease 
Acetate (C2) is the most abundant SCFAs in the gut. Its concentration is up to 
130mM in the colon and 1mM in the blood. To examine the role of SCFAs in the renal 







than normal gut concentration. Compared to normal water, mice did not consume more or 
less C2 water (Fig. 3.1 A). However, six weeks of C2 feeding significantly increased C2 
concentrations in the blood and kidney tissues (Fig. 3.1. B and C). Specifically, C2 feeding 
elevated concentrations of C2 in kidney tissues from 0.56 ± 0.079 mM to 2.78 ± 1.02 mM. 
When we examined mice after 6 weeks of C2 water, we found irregularly shaped kidneys. 
Kidneys were bloated with hydronephrosis in the C2-fed group and we named the kidney 
disease C2RD. However, the same concentration of NaCl (200mM) hardly affected the 
kidneys, and we ruled out the role of sodium ion (Na+) in C2RD (Fig 3.2 A). Kinetic 
observation showed that about 30% of mice had C2RD after four weeks of C2 feeding and 
most mice developed C2RD by the sixth week of treatment (Fig 3.2 B). Sectioned kidney 
tissues revealed that the medulla structure of C2RD mice was severely impaired and the 
cortex was squeezed (Fig 3.2 C). In addition, we observed that 55% of C2RD was in only 
one side of the kidney (Fig. 3.2 D). The renal function was evaluated by creatinine and urea 
levels in the serum or urine. As expected, C2RD mice showed increased concentrations in 
the serum while urinal levels of creatinine and urea were decreased (Fig. 3.3 A). Systolic 
blood pressure was also higher in C2RD mice (Fig. 3.3 B).  
We titrated minimal C2 concentration that develops C2RD, and found that 150mM 
of C2 induced disease in 30% of mice but not at 100mM (Fig 3.4). The disease rate of 
C2RD was about three times higher in males than females (Fig. 3.5), which correlates with 







to augmented C2 developed renal disease and disrupted kidney function in dose-and time-
dependent manners.  
 
Change of T cell and gene expression profiles in C2RD kidney tissues 
Drastic changes in kidney tissue as a result of C2, prompted us to investigate 
immune cell profiles of C2RD. Using immunofluorescence microscopy, we found CD4+ T 
cells and CD11c+ cells were highly infiltrated in C2RD kidney tissues (Fig. 3.6 A). We 
further examined the kinetics of T cell subsets via C2 water feeding. Four weeks or longer 
of C2feeding increased the expressions of both effector and regulatory T cells (Fig. 3.6 B). 
Because the infiltration of inflammatory cells and fibrosis in renal tissues are associated 
with the secretion of cytokines or chemokines, we examined the expressions of related 
genes by qRT-PCR. Inflammatory cytokines and chemokines Il6, Il17a, Ifng, Ccl2, Ccl5, 
and Ccl17 were increased at mRNA level. In addition, levels of regulatory or fibrosis-
related cytokine genes, such as Il10 or Tgfb1, were also upregulated in the affected kidney 
tissues (Fig. 3.7).  
Changes of immune cells and their signature genes in C2RD showed similar 
patterns as other renal inflammation (51, 110, 111). To characterize the gene expression of 
C2RD, we applied a microarray analysis. We compared C2RD with unilateral ureteral 
obstruction (UUO), congenital obstructive nephropathy in the male megabladder (Mgb)−/− , 
lupus nephritis, and embryonic polycystic kidney disease (PKD) models (112-115). In 
terms of transcriptome levels, C2RD had adjacent relations to UUO and Mgb−/− models, 
but less correlation with Lupus or PKD (Fig. 3.8 A). C2RD also showed functional 







proliferation (Fig. 3.8 B). The results indicate that C2RD shares immunological changes 
with other renal diseases, especially obstructive ureter models. 
 
Ureteral obstruction and inflammation in C2RD 
Because C2RD showed features analogous to ureteral obstruction disease, we 
closely investigated the ureteral area in C2RD mice. Histological analysis of kidney tissues 
showed signs of inflammation in both the cortex and medulla regions as C2RD progressed 
(Fig. 3.9 A). Ureteropelvic junction (UPJ) obstruction leads to obstructive renal disease in 
humans and animals (116), and we observed severe hyperplasia and immune cell 
infiltration in C2RD mice (Fig. 3.9 B). To confirm the ureteral obstruction in C2RD mice, 
we injected India ink into the kidneys. The ink flow was completely blocked from the 
pelvic area to the bladder. Moreover, HnE staining revealed obstructed UPJ in C2RD mice 
(Fig. 3.10 A and B). In the proximal ureter, we observed hyperplasia of tissue via the 
longitudinal section (Fig. 3.11 A). We measured the thickness changes in epithelium, 
lamina propria, muscular and adventitia layers. Each compartment was expanded with C2 
water administration (Fig. 3.11 B). However, ureteral stones were not detected with a Von 
Kossa staining method in the affected ureters (Fig. 3.12). These results suggest that C2RD 
is subsequently caused by ureteral obstruction. 
 
 T cell subset changes in C2RD ureter 
We previously identified the ureter as the target organ of C2RD. Therefore, we 
examined the changes in the ureter immune cells. In affected ureters, CD4+ T cells and Gr-







which reflects fibrosis, was also heavily deposited in these area (Fig. 3.13). Then, we found 
effector (Th1 and Th17) and regulatory (IL-10+ and FoxP3+) T cell expansion in the C2-
fed ureters (Fig. 3.14). Moreover, we examined the increased numbers of effector and IL-
10+ T cells in kidney tissues in a C2-dose dependent manner (Fig. 3.15A). The enlarged 
renal draining lymph nodes indicate the activation of immune cells in C2RD mice (Fig 
3.15B). Additionally, we compared the kinetics of T cell subsets in systemic or renal tissues. 
Although splenic T cells were unaffected, four weeks or longer ofC2 feeding increased 
total CD4+, effector, and regulatory T cells in each renal tissue sample (Fig. 3.16). To gain 
comprehensive information from required C2 administration periods, mice were fed C2-
infused water for four weeks and switched to regular water for the following two weeks. 
Withdrawing C2 after the fourth week protected mice from C2RD (Fig. 3.17). Here, we 
found that extended exposure to C2 is required for C2RD development, in which renal T 
cells are augmented. 
 
T cell requirement in C2RD development 
So far, we have demonstrated that T cells are plentiful in affected renal tissues. To 
investigate the role of T cells in C2RD pathogenesis, we attempted to induce C2RD in T 
cell (αβ-TCR)-deficient mice. Interestingly enough, C2 was unable to promote C2RD 
development in T cell-lacking conditions (Fig 3.18). Because expressions of effector T cell 
cytokines increased in the renal tissue of C2RD mice, we investigated the role of these 
cytokines in C2RD development. We injected neutralizing antibodies of IL-17 or IFNγ 
along during a six-week-long C2 treatment. Blocking antibodies significantly suppressed 







Frequencies of Th17, Th1, or IL-10+ T cells decreased after antibody treatment (Fig. 3.19B).  
Therefore, we determined that T cells and their cytokines are required for C2RD 
pathogenesis. 
 
Impact of other SCFAs and SCFAs receptors on C2RD 
Propionate (C3) and butyrate (C4) are other major SCFAs. We investigated whether 
like C2RD, C3, or C4 are capable of inducing renal disease. The administration of C3 and 
C4 at the same concentration (200 mM) developed hydronephrosis as efficiently as C2 (Fig. 
3.20A). The populations of effector and IL-10+ T cells in renal tissues increased after C3 
or C4 feedings (Fig 3.20B). We confirmed its similarity to C2-induced disease with 
histological analysis, which affected kidney structures and ureter hyperplasia (Fig 3.20 C). 
 SCFAs act as ligands of GPR41 or GPR43, and activate cellular processes in 
various cell types, such as gut epithelium or neutrophils (37, 38). To examine the 
involvement of GPR41 or GPR43 in C2RD development, we first determined the mRNA 
expression levels of Gpr41 or Gpr43 in the kidneys and ureter tissues. Compared to colon 
tissue, expressions of Gpr41 and Gpr43 were limited in renal tissues (Fig. 3.21). Thus, C2 
administration to GPR41- and GPR43-deficient mice developed C2RD as efficiently as 
WT mice. Both knockout strains showed increased disease rates, kidney weights, and 
effector T cells in the affected kidneys (Fig. 3.22A and B). 
 
Gut microbiota and age-dependent C2RD development 
Because SCFAs are produced by gut microbiota, we questioned if bacterial 







that C2 administration expanded Bacteroidetes, while segmented filamentous bacteria 
(SFB) and Actinobacteria were reduced (Fig. 3.23A). To examine the effect of gut 
microbiota on C2RD pathogenesis, we fed vancomycin (along with) C2 in drinking water. 
Vancomycin eradicates Firmicutes and Bacteroidetes (117, 118), and the oral feeding of 
vancomycin plus C2 water completely protected mice from C2RD development (Fig. 
3.23B).  
In humans, UPJ obstruction rates are higher in younger populations (119), and we 
investigated if C2RD occurrence is age dependent. We exposed 3- and 32-week-old mice 
to C2 water for 6 weeks. C2 induced less C2RD in older mice than in younger mice (Fig. 
3.24). We provide the evidence that intestinal microbiota and age affect the C2RD 
pathogenesis. 
 
Impact of SCFAs on mTOR pathway and inflammatory T cells in C2RD 
Activation of mTOR pathways supports effector and IL-10+ T cell differentiation, 
and we reported that SCFAs stimulate mTOR activity in T cells. Because renal 
inflammation can be controlled by mTOR inhibition (60-63, 120, 121), we examined 
whether mTOR-mediated T cell activation is involved in C2RD development. First we 
cultured the total cells in the renal draining lymph nodes (dLN) in the presence of SCFAs 
and rapamycin. The phosphorylation level of the ribosomal S6 protein (rS6), a key target 
of mTOR pathways, were examined in dLN T cells. SCFAs enhanced the activity of rS6, 
which was abolished with rapamycin addition (Fig. 3.25A). SCFAs also enhancedIL-17+ 
or IFNγ+ T cell differentiation, but SCFA-promoted effector T cell generation was blocked 







effects on C2RD development. Rapamycin-infused drinking water effectively blocked 
C2RD development (Fig. 3.26A). In the affected kidney tissues, rS6 activity and effector 
T cell generation escalated while rapamycin feeding counteracted C2 effects (Fig. 3.26B 
and C). These consequences imply that SCFAs regulate effector T cell differentiation in 




This study demonstrates the inimical effect of SCFAs on the renal system. 
Unexpectedly, the chronological elevation of SCFA levels induced ureteral obstruction and 
developed hydronephrosis in T cell-dependent fashions. In affected kidneys, mTOR 
pathways stimulated the expansion of inflammatory T cells. These results suggest that 
SCFAs have pro-inflammatory roles in reinforcing effector T cell generation. 
SCFAs produced by gut microbiota and C2 concentrations reach up to 130mM in 
the large intestinal region (3, 4). Feeding 200mM of C2water increased C2 concentration 
in the blood and kidney by 1.5 and 4 times respectively. Although the same dose of NaCl 
hardly affected renal tissues, prolonged exposure to C2 induced UPJ obstruction formed a 
huge sac in the kidneys, which we named C2RD. We compared the transcriptome of C2RD 
to other kidney diseases including UUO, congenital ureteral obstruction, Lupus, and PKD. 
We found that C2RD gene expression patterns most closely resemble ureteral obstruction 
models. In functional groups, C2RD also showed similarities to the UUO model. In 







induce ureteral obstruction (122, 123). However, C2RD does not originate from these 
factors. Von Kossa staining did not detect ureteral stones and C2RD was detected in adult 
wild-type mice. Indeed, C2RD development was independent of the SCFA receptors, 
GPR41 and GPR43. 
Instead, we found the role of the T cell as a major player in C2RD pathogenesis. In 
αβ T cell-deficient mice, C2 administration scarcely induced C2RD, which implies that T 
cells are required for disease development. In ureteral obstruction diseases, effector T cells 
expanded and their expression of inflammatory cytokines contributes to inflammation (45, 
50). In our previous study, we reported that SCFAs facilitate effector T cell differentiation 
(44). In this regard, Th1 and Th17 cells expanded following SCFA feeding and 
subsequently developed renal inflammation. This demonstrates the role of SCFAs in renal 
effector T cell generation. Furthermore, we verified the function of effector cell-producing 
cytokines by neutralizing IL-17 and IFNγ, which abolished C2RD development. SCFAs 
also regulate regulatory T cell generation, such as IL-10+ or FoxP3+ T cells in various 
organs (11, 29-31, 44). A recent study reported the protective role of SCFAs in lessening 
inflammatory processes in acute kidney injuries (69). We observed expanded populations 
of regulatory T cells in C2RD mice, further evidence of the action of SCFAs on regulatory 
T cells in the renal system. However, we suggest that the increase was due to general 
activation of T cells in inflammatory conditions (124-126), and increased regulatory T cells 







regulate T cell differentiation according to the environment (e.g. the intensity of T cell 
activation or pathogen infection). 
mTOR pathways are activated when effector T cells are induced. SCFAs are able 
to promote both regulatory and effector T cells by stimulating mTOR-S6K signals (44). In 
many renal diseases, such as UUO, Lupus or PKD, mTOR pathways were activated. In 
these cases, rapamycin effectively prevented renal inflammation (115, 127, 128). In C2RD, 
the mTOR activity of renal CD4+ T cells and the population of effector T cells increased. 
Administration of rapamycin in drinking water prohibited C2RD development by 
mitigating mTOR activity and effector T cell expansion.  
Along with T cells, it is possible that non-T cell or other elements coordinate C2RD 
pathogenesis. Besides CD4+ T cells, a number of CD11c+ dendritic cells (DCs) were 
detected in C2RD kidney tissues. The role of DCs in renal inflammation is clearly 
demonstrated by numerous studies. In DC-depleted conditions, UUO kidneys showed 
decreased effector T cell populations, and inflammation was suppressed (51).  
Intestinal microbiota is recognized as an important player in C2RD development. 
SCFAs are gut metabolites, and SCFA feedings changed the composition of major 
microbiota. The role of commensal bacteria in autoimmune diseases, such as multiple 
sclerosis, colitis, diabetes, or rheumatoid arthritis, was suggested (129-131). In line with 
previous works, antibiotic feeding completely suppressed C2RD. While underlying 
mechanisms need to be investigated, we consider that vancomycin treatment abolished C2-
induced bacterial composition and blocked C2RD progress. Besides, we observed that age 







more frequent in younger and male mice. This suggests that C2RD has the potential to be 
used in a human renal disease model. Compare to the UUO model, C2RD does not require 
surgery to address the artificial ureter obstruction. The natural progress of ureteral 
obstruction, which leads to hydronephrosis can offer a useful disease model. 
To take advantage of this study, prolonged exposure to uplifted-SCFAs can induce 
Th1 or Th17 cell-mediated inflammation in renal tissue. Oral SCFA delivery regulated 
mTOR dependent T cell differentiation with the help of gut microbiota. We suggest that 
SCFAs, along with environmental factors, have the potential to induce renal inflammation 
via effector T cell generation. 
 
3.5 Summary and future directions 
 
3.5.1. Summary of the study 
We reported that prolonged exposure to high doses of SCFAs develops ureteral 
obstruction and hydronephrosis, which we named C2RD. T cell had essential role in C2RD 
pathogenesis and SCFAs expand renal effector T cell in a mTOR-dependent manner. Gut 
microbiota are also required to promote C2RD in combination with SCFAs. In addition, 
we found age and sex influence the occurrence of C2RD. However, the expression of 
SCFAs receptors, GPR41 and GPR43 were least significant in renal tissue and not involved 









3.5.1. Future study directions 
In this study, we mainly discussed the role of T cells in SCFA-mediated renal 
inflammation. In affected kidneys, we also found increased population of CD11C+ cells, 
which presumes the role of dendritic cells (DCs) in C2RD development. Kidney resident-
DCs activate renal dLN T cells through antigen presentation or cytokine secretion, which 
develops into kidney inflammation (51, 132). Although the effect of SCFAs on DCs 
regulation is unclear, a study reported that C4 enhance IL-23 expression in LPS-stimulated 
bone marrow-derived DCs. Moreover, a co-culture of C4-treated DCs increased IL-17 
expression in splenic T cell (133). Accordingly, cytokine expression in SCFA-treated renal 
DCs need to be examined. These DCs should be co-cultured with T cells and induction of 
effector T cell will be determined. To confirm the role of renal DCs in C2RD in vivo, 
CD11c-DTR mice or clodronate liposomes injection methods can be applied in C2RD-


















Figure 3.1 Amount of oral acetate (C2) drinking and concentrations of SCFA in blood 
and kidneys. 
(A) Measurement of the consumed water (ml/g body weight/week) in control or C2-
allocated group. SCFA concentrations in serum (B) or kidney tissues (C) were determined 
in normal water and C2-infused water-fed mice. The water treatment was for six weeks. 















Figure 3.2 Acetate (C2, 200 mM)-infused water induced a renal disease (C2RD). 
(A) C2 (200 mM) or NaCl (200 mM) were treated via drinking water for six weeks and 
induced hydronephrosis. Gross images of kidney tissues, disease rate, and kidney weight 
are shown. (B) Kinetics of C2-induced renal disease (C2RD) rate and kidney weight are 
shown. (C) Sectioned images of normal or C2RD kidney tissues. (D) Occurrence of 
unilateral or bilateral C2RD. Representative and pooled data are shown (n=6-15). 









Figure 3.3 Renal function and blood pressure in C2RD mice. 
(A) Creatinine and urea concentrations in serum or urine were measured. Normal and 
C2RD mice were compared. (B) Blood pressure was determined after C2- or NaCl-water 
feeding for six weeks. Pooled data from five to eight individual mice are shown. 


















Figure 3.4 Occurrence of C2RD in a C2 dose-dependent manner. 
Different C2 doses in drinking water. Mice were administered C2 water for six weeks. 
Disease rate and weight of kidneys are shown in indicated groups. Representative or pooled 
data from six to nine mice are shown. *Significant differences from non-treated group (P≤ 













Figure 3.5 Sex biased C2RD development. 
C2RD occurrence and kidney weights were compared between male and female mice. 
Pooled data from fourteen mice are shown. *Significant differences from male group (P≤ 



















Figure 3.6 Kinetic changes of immune cells in C2RD kidney tissues. 
(A) Infiltration of CD4+ or CD11c+ cells in kidney tissues identified with confocal analysis. 
(B) Frequencies of T cell subtypes determined by flow cytometry, which gated for CD4+ 
T cells in kidney tissues. Dot plots shown from control or six weeks-fed mice. 
Representative or pooled data from six individual mice are shown. *Significant differences 










Figure 3.7 Expressions of cytokines, chemokines, and chemokine receptors in C2RD 
kidney tissues. 
Kidney tissues were collected from normal and C2RD mice. Expression of cytokines (A), 
chemokines, or chemokine receptors (B) examined at mRNA level by qRT-PCR. Pooled 
data from three to six different tissues are shown. *Significant differences from control 














Figure 3.8 Comparative analysis of transtriptome among C2RD and other renal 
diseases. 
(A) Gene expressions of C2RD kidney tissues compared with UUO, Mgb-/- congenital 
obstructive nephropathy, lupus nephritis, and polycystic kidney disease (PKD) (B) Genetic 
relationships between C2RD and UUO or PKD in functional groups. Microarray analysis 
of C2RD genes is shown based on published gene expression data in the Gene Expression 
Omnibus database for UUO, Mgb-/-, Lupus, and PKD models. Pearson coefficient (r) 









Figure 3.9 Histological analysis of C2RD kidney tissues. 
(A) Kidney tissue sections were prepared at different developmental stages of C2RD and 
stained with hematoxylin and eosin (HnE). (B) Focused images of ureteropelvic junction 








Figure 3.10 Ureteral obstruction in C2RD mice. 
(A) Ureteral obstruction was evaluated. India ink was injected into the kidney pelvic area 
of normal and C2RD mice. (B) Histological analysis of ureteral obstruction in normal and 



















Figure 3.11 Ureteral hyperplasia in C2RD mice. 
(A) Histological analysis of ureteral hyperplasia in C2RD mice. Longitudinal sections were 
obtained from proximal ureters and stained with HnE. (B) Changes in ureteral thickness 
were measured with cross sections. Each color of bar graph indicates the diameter of the 
ureteral structure. Original magnification ×100 (A) and ×25 (B). *Significant differences 













Figure 3.12 Von Kossa staining of ureter tissues 
A mouse femur bone was used as a positive control. Representative data from at least four 












Figure 3.13 Changes in immune cells of C2RD ureter tissues. 
Infiltrations of CD4+, Gr-1+, smooth muscle cells (actin), epithelial cells (cytokeratin), and 
collagen IV expression were represented with fluorescent conjugated antibodies using 
confocal analysis. Cross sections of proximal ureters in normal or C2RD mice were 












Figure 3.14 Effector or regulatory T cell changes in C2RD ureter tissues. 
Numbers and frequencies of total CD4+ T cells, effector T cells (Th17 and Th1) and 
regulatory T cells (IL-10+ and FoxP3+ T cells) are determined by flow cytometry, which 
gated for CD4+ T cells in ureteral tissues. Pooled data or representative dot plots are from 












Figure 3.15 C2 dose-dependent changes of renal T cells in C2RD. 
(A) Changes in the T cell numbers of kidneys at different doses of C2. (B) Aggrandized 
renal draining lymph nodes (dLN) with C2RD. Mice were fed with C2 water at indicated 
concentrations for six weeks and T cell numbers were determined by flow cytometry. 
Representative images or pooled data were obtained from six individual mice. *Significant 















Figure 3.16 Kinetic changes in T cell numbers duringC2RD development. 
Cells from spleen, dLN, kidneys or ureters were collected from C2-fed mice at indicated 
time points. To evaluate the T cell expansion, antibodies to CD4, IL-17, IFNγ, IL-10, or 
FoxP3 were applied and the numbers of CD4+ cell, Th1, Th17, IL-10+, and FoxP3+ T cells 
were examined by flow cytometry. Pooled data were obtained from six individual mice. 









Figure 3.17 C2RD development by continuous exposure to C2. 
C2 water was administered to mice for four weeks and switched to normal water for an 
additional two weeks, and C2RD development was compared to six weeks’ feeding of C2. 
The effect of C2-withdrawal was investigated with gross images of renal tissues (A), 
disease rate (B), and kidney weight (C). Representative and pooled data are shown (n=6-















Figure 3.18 Role of T cells in C2RD development. 
Gross images of renal tissues, disease rates, and relative kidney weights are shown. Wild-
type (WT) or T cell (αβ-TCR)-deficient (TCD) mice were fed with regular or C2 (200 
mM)-containing drinking water for six weeks. Representative or pooled data from eight 










Figure 3.19 Roles of IL-17 and IFNγ in C2RD development. 
(A) Gross images of renal tissues, disease rates, and relative kidney weights are shown. 
Mice were injected with neutralizing antibodies to IL-17 or IFNγ (100 μg/mouse, once a 
week) during the C2 feeding. (B) Frequencies of renal Th17, Th1, and IL-10+ T cells were 
determined by flow cytometry. Representative images and pooled data from six to eight 









Figure 3.20 C2RD development by other SCFAs propionate (C3) and butyrate (C4). 
(A) Gross images of renal tissues, disease rates, and relative kidney weights are shown. 
Mice were fed with C3 (200 mM) or C4 (200 mM)-infused drinking water for six weeks. 
(B) T cell number changes in the dLN, kidneys, or ureter tissues were examined by flow 
cytometry. (C) Histology of kidneys and proximal ureters were observed with HnE staining. 
Original magnification ×50 (kidneys) and ×100 (ureters). Representative and pooled data 










Figure 3.21 Expression of SCFA receptors GPR41 and GPR43. 
Expression of Gpr41 and Gpr43 at mRNA level were determined by qRT-PCR. RNA was 
isolated from indicated tissues in WT and GPR-deficient mice. Pooled data from three 
















Figure 3.22 Role of GPR41 and GPR43 in C2RD development 
(A) Gross images of renal tissues, disease rates, and relative kidney weights are shown. 
C2-water was administered to WT-, GPR41- or GPR43-deficient mice for 6 weeks. 
Frequencies of renal Th17, Th1, or IL-10+ T cells were examined by flow cytometry. 
Representative images and pooled data from six to eight individual mice are shown. 










Figure 3.23 Role of gut microbiota in C2RD development 
(A) The composition of selected gut microbiota is determined by qPCR using group-
specific 16S rRNA sequences. Bacterial DNA from fecal material was isolated from 
normal or C2RD mice. (B) Mice were administered C2 water for six weeks in the presence 
or absence of vancomycin (0.5 g/L). Gross images of kidney tissues, C2RD rates, and 
relative kidney weight are shown. Representative image or pooled data six to eight 
individual mice are shown. *Significant differences from control or C2-alone groups (P≤ 










Figure 3.24 Effect of age on C2RD development. 
Mice were fed C2-containing water for six weeks from the age of three week (younger) or 
thirty two weeks (older). Gross images of renal tissues, relative kidney weights, and disease 
rates are shown. Representative images and pooled data from six to eight individual mice 













Figure 3.25 Effect of SCFAs and rapamycin on mTOR activity or effector T cell 
differentiation of renal dLN-T cells. 
Total renal lymph node cells were activated with anti-CD3 in the presence of SCFAs and 
rapamycin (mTOR inhibitor). (A) mTOR activity among CD4+ T cells was examined after 
three-day activation in Tnp polarizing condition. Levels of rS6 phosphorylation were 
evaluated by flow cytometry. (B) Differentiation into effector (IL-17+ or IFNγ+) T cells 
was examined after a five or six day culture in Th1 or Th17 polarizing conditions. 
Representative dot plots or pooled data from four experiments are shown. *Significant 










Figure 3.26 Role of rapamycin in C2RD development. 
(A) Gross images of renal tissues, disease rates, and relative kidney weights are shown. 
Mice were fed normal or C2-water in the presence or absence of rapamycin (25 μg/ml) for 
six weeks. (B) mTOR activity (phosphorylation of rS6) in renal CD4+ T cells in rapamycin-
and/orC2-fed mice was examined by flow cytometry. (C) Effect of rapamycin and/or C2 
administration on effector T cell numbers is shown. Representative images and pooled data 
from seven to ten individual mice are shown. *Significant differences from indicated 













Figure 3.27 Impact of SCFAs on T cell in development of renal inflammation 
Oral SCFAs feeding induced a chronic ureter hyperplasia and hydronephrosis. In affected 
tissues, inflammatory T cells were highly infiltrated, while T cell-deficient condition 
blocked disease development. Rapamycin a mTOR inhibitor, or neutralizing antibodies of 
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